Author: Editor

How effective is mosunetuzumab in treating lymphoma? – Elizabeth Budde, MD 2023 reviews new therapies By Elizabeth Budde, Md, PhD Thank you so much for the invitation. This is actually my first time joining the meeting and it’s been very exciting. I’m learning a lot about medical oncology and all the exciting new drugs. Now, some of the naturally, pretty similarly are also using the in the domain.. How do I get started? Oh, great. Yeah, so I was assigned the task to talk about novel regimens and agents in lymphoma. So it’s a switch from medical oncology, but I…

Lung Cancer Trials: Insights into Latest Clinical Trials in Thoracic Oncology – Expert Analysis from Ravi Salgia, MD By Ravi Salgia, MD, PhD Thank you. After that introduction, I think my time is over, we can take questions now. If I can have my first slide. So for today, it’s a whirlwind of a talk to talk about lung cancer and we’ve certainly come a long way, but I’ll try to emphasize EGFR, KRAS, ALK and immunotherapy for non-small cell lung cancer. Lung cancer, as is a quite devastating illness. I’ve been in practice for over 33 years now and…

Belzutifan and other Novel Therapies in Genitourinary Oncology 2023 By Rana McKay, MD – University of California San Diego We’re gonna start with kidney cancer and go through Belzutifan, Relatlimab, SRF-388 and the others that are listed here. Then we’ll go into. And finally urothelial cancer. This is gonna be a little bit of a whirlwind, splash on each of these drugs where they’re at. And then tie it all up at the end. Renal Cell Carcinoma 2023 Update So we’ll start with kidney cancer and first we’ll talk about Belzutifan. and it’s, I have to say it’s been amazing…

Gastrointestinal Malignancies Research Advancements: Insights from Farshid Dayyani, MD By Farshid Dayyani, MD, PhD Thank you so much for inviting me to this meeting. I was asked to give an overview of research in GI malignancies, and I made 200 slides. Then I realized we have 25 minutes. I practiced this morning. I can’t do it in 18 minutes, so it will be a very concise, here’s my disclosures. What I will try to do is I think I’ll show you very recent data, let’s say the past year or so, where I think the practice might change based on…

Health Inequity in Cancer Research: Examining and Uncovering the Disparities by Hala Borno MD By Hala Borno, MD What also energizes me is that while I was walking down here, I was smiling because I actually got married in this hotel about 10 years ago in the ballroom where the NAFFLE Conference is going on right now. It is just very interesting nostalgia that I was experiencing, but I am delighted to be here and very grateful for the invitation to speak with you. So today I’ll be talking about a topic that’s very near and dear to my heart,…

Leptomeningeal Disease: Phase 1 Trial of BBB-Penetrant HER2 Inhibitor in Metastatic Breast Cancer Nicholas McAndrew MD By Nicholas McAndrew, MD, MSCE DZD1516 is a is a new compound, it’s a new oral tyrosine kinase inhibitor that was designed by the company. When the company initially was developing this drug. They were seeking compounds that were going to be highly HER2 selective and blood-brain barrier penetrant. Because HER2 positive breast cancer is a high rate of CNS metastases, and so it remains 1 of the biggest challenges, although we do now have some compounds out on the market like Tucatinib and…

Polygenic Risk Score: Validation of a Breast Cancer Risk Prediction Model in a Large Prospective Cohort Thomas Slavin, MD By Thomas Slavin, MD When we think about polygenic risk score, it is fairly new. We are doing a lot of the innovation at Myriad. We’ve been doing a lot to restructure the company focused down on women’s health, oncology, mental We’re thinking very differently. We’re trying to be more collaborative, unique access and equity advancements and continue to innovate really heavily in that area. And this is really one of those examples where we saw amazing science going on in…

Endocrine Therapy: 70-Gene MammaPrint Test Predicts Benefit in Early-Stage Breast Cancer Laura Van ’t Veer By Laura Van ‘t Veer, MSC, PhD Breast cancer patients who are diagnosed with breast cancer that is endocrine sensitive. So those tumors that are estrogen receptor positive, their standard of treatment is 5 years of endocrine treatment, Tamoxifen or tyrosine kinase inhibitor. So recent trials have shown that an extension of that 5 years to 10 years benefits patients that which there’s some benefit in survival. But the question has been for some time, who benefits because it’s only a modest benefit and the…

NanoString: Intrinsic Subtypes and 21-Gene Assay Predict Recurrence in Early Stage HER2+ Breast Cancer from Saranya Chumsri MD By Saranya Chumsri, MD Breast cancer is a complex disease with many different subtypes that can impact treatment decisions and patient outcomes. HER2-positive breast cancer is a subtype that is characterized by the overexpression of the HER2 protein, and accounts for approximately 20% of all breast cancer cases. The North Central Cancer Treatment Group (NCCTG) N9831 (Alliance) Trial was a large, randomized clinical trial that evaluated the use of chemotherapy and trastuzumab (Herceptin) in the treatment of HER2-positive breast cancer. The…

Breast Cancer Index: Prospective Evaluation Insights from Kai Treuner PhD By Kai Treuner, PhD So the breast cancer index is a test that’s been developed for the extended endocrine decision making. So in particularly women that are hormone receptor positive that usually get 5 years of endocrine therapy at the 5 year point they have to face the question, is extension of that endocrine therapy beneficial for me or not? So that’s the answer that the BCI provides the breast cancer index we are providing a prognostic answer. So what is the risk of recurrence as well as the prediction…

PACE Trial: Palbociclib, Fulvestrant, and Avelumab in Endocrine Pre-treated Metastatic Breast Cancer Erica Mayer MD By Erica Mayer, MD So a very important standard of care for our patients with metastatic hormone receptor positive HER2-negative breast cancer is using a CDK4/6 inhibitor in combination with endocrine therapy. These are wonderful medicines and they provide great benefit for patients, however, eventually the cancer progresses and a big question has been, when is it time to change therapy? Do you change the, just the endocrine therapy and continue the CDK4/6 inhibitor, or is it time to stop the CDK4/6 inhibitor? So the…

Polygenic Risk Score: Validation of a Breast Cancer Risk Prediction Model in a Large Prospective Cohort Thomas Slavin, MD By Thomas Slavin, MD When we think about polygenic risk score, it is fairly new. We are doing a lot of the innovation at Myriad. We’ve been doing a lot to restructure the company focused down on women’s health, oncology, mental We’re thinking very differently. We’re trying to be more collaborative, unique access and equity advancements and continue to innovate really heavily in that area. And this is really one of those examples where we saw amazing science going on in…

Endocrine Therapy: 70-Gene MammaPrint Test Predicts Benefit in Early-Stage Breast Cancer Laura Van ’t Veer By Laura Van ‘t Veer, MSC, PhD Breast cancer patients who are diagnosed with breast cancer that is endocrine sensitive. So those tumors that are estrogen receptor positive, their standard of treatment is 5 years of endocrine treatment, Tamoxifen or tyrosine kinase inhibitor. So recent trials have shown that an extension of that 5 years to 10 years benefits patients that which there’s some benefit in survival. But the question has been for some time, who benefits because it’s only a modest benefit and the…

NanoString: Intrinsic Subtypes and 21-Gene Assay Predict Recurrence in Early Stage HER2+ Breast Cancer from Saranya Chumsri MD By Saranya Chumsri, MD Breast cancer is a complex disease with many different subtypes that can impact treatment decisions and patient outcomes. HER2-positive breast cancer is a subtype that is characterized by the overexpression of the HER2 protein, and accounts for approximately 20% of all breast cancer cases. The North Central Cancer Treatment Group (NCCTG) N9831 (Alliance) Trial was a large, randomized clinical trial that evaluated the use of chemotherapy and trastuzumab (Herceptin) in the treatment of HER2-positive breast cancer. The…

Breast Cancer Index: Prospective Evaluation Insights from Kai Treuner PhD By Kai Treuner, PhD So the breast cancer index is a test that’s been developed for the extended endocrine decision making. So in particularly women that are hormone receptor positive that usually get 5 years of endocrine therapy at the 5 year point they have to face the question, is extension of that endocrine therapy beneficial for me or not? So that’s the answer that the BCI provides the breast cancer index we are providing a prognostic answer. So what is the risk of recurrence as well as the prediction…

PACE Trial: Palbociclib, Fulvestrant, and Avelumab in Endocrine Pre-treated Metastatic Breast Cancer Erica Mayer MD By Erica Mayer, MD So a very important standard of care for our patients with metastatic hormone receptor positive HER2-negative breast cancer is using a CDK4/6 inhibitor in combination with endocrine therapy. These are wonderful medicines and they provide great benefit for patients, however, eventually the cancer progresses and a big question has been, when is it time to change therapy? Do you change the, just the endocrine therapy and continue the CDK4/6 inhibitor, or is it time to stop the CDK4/6 inhibitor? So the…

Open Label Phase III TIGeR-PaC Interim Data Observes 6-Month Median Survival Benefit: RenovoGem (Intra-Arterial Gemcitabine) Versus IV Gemcitabine and nab-paclitaxel for Pancreatic Cancer Treatment By Michael Pishvaian, MD, PhD Locally advanced pancreatic cancer has its own challenges because we’re really focused on trying to treat the tumor where it lies within the pancreas, while also treating the systemic micro metastatic disease that almost certainly is there. It’s also not usually a situation where we’re trying to get the patient to the point of operability. Unfortunately, we know that at least 85% of patients with locally advanced, unresectable pancreatic cancer, as…

Antibody-Drug Conjugate Advancements for Breast Cancer Treatment: Updates from SABCS 2022 by Leif Ellisen MD By Leif Ellisen, MD So antibody drug conjugates, or as I’ll refer to them, ADCs are a really important new class of drugs. They’re very complicated structure in that they have three distinct components. One is an antibody that binds to a target on the surface of the tumor cell. That antibody is linked or conjugated to what we call a “cytotoxic payload,” typically a chemotherapy like drug, and when it’s linked to the antibody, that chemotherapy drug is carried into the cell. When the…

Invasive Lobular Breast Cancer: Steffi Oesterreich Shares Insightful Learning Sessions Exploring ILBC at SABCS 2022 By Steffi Oesterreich, PhD So, I was very excited about increasing attention to special subtypes of breast cancer. There was actually a unique session, an educational session called Challenging Types of Breast Cancer: Lobular/Pleomorphic, and I was very excited because invasive lobular breast cancer, which affects approximately 10 to 15% of all breast cancers, received quite a bit of attention there. I think in prior years that didn’t happen so much here at the San Antonio Breast Cancer Symposium (SABCS), so this was really…

Binimetinib: Combination Insights on the Treatment Strategy of Breast Cancer from SABCS 2022 Saranya Chumsri MD By Saranya Chumsri, MD This particular study is a phase 1/2 trial of Pembrolizumab in combination with Binimetinib (brand name MEKTOVI), which is a MEK inhibitor. So previous preclinical and clinical studies show that activation of the MAP kinase pathway is associated with a reduction in the tumor infiltrating lymphocytes, and when we use the MEK inhibitor in combination with the anti-PDL1, it’s actually synergistic in the clinical model, which led us to conduct this particular trial. Right now the current standard of…

Open Label Phase III TIGeR-PaC Interim Data Observes 6-Month Median Survival Benefit: RenovoGem (Intra-Arterial Gemcitabine) Versus IV Gemcitabine and nab-paclitaxel for Pancreatic Cancer Treatment By Michael Pishvaian, MD, PhD Locally advanced pancreatic cancer has its own challenges because we’re really focused on trying to treat the tumor where it lies within the pancreas, while also treating the systemic micro metastatic disease that almost certainly is there. It’s also not usually a situation where we’re trying to get the patient to the point of operability. Unfortunately, we know that at least 85% of patients with locally advanced, unresectable pancreatic cancer, as…

iFrame is not supported! Antibody-Drug Conjugate Advancements for Breast Cancer Treatment: Updates from SABCS 2022 by Leif Ellisen MD By Leif Ellisen, MD So antibody drug conjugates, or as I’ll refer to them, ADCs are a really important new class of drugs. They’re very complicated structure in that they have three distinct components. One is an antibody that binds to a target on the surface of the tumor cell. That antibody is linked or conjugated to what we call a “cytotoxic payload,” typically a chemotherapy like drug, and when it’s linked to the antibody, that chemotherapy drug is carried into…

iFrame is not supported! Invasive Lobular Breast Cancer: Steffi Oesterreich Shares Insightful Learning Sessions Exploring ILBC at SABCS 2022 By Steffi Oesterreich, PhD So, I was very excited about increasing attention to special subtypes of breast cancer. There was actually a unique session, an educational session called Challenging Types of Breast Cancer: Lobular/Pleomorphic, and I was very excited because invasive lobular breast cancer, which affects approximately 10 to 15% of all breast cancers, received quite a bit of attention there. I think in prior years that didn’t happen so much here at the San Antonio Breast Cancer Symposium (SABCS),…

iFrame is not supported! Binimetinib: Combination Insights on the Treatment Strategy of Breast Cancer from SABCS 2022 Saranya Chumsri MD By Saranya Chumsri, MD This particular study is a phase 1/2 trial of Pembrolizumab in combination with Binimetinib (brand name MEKTOVI), which is a MEK inhibitor. So previous preclinical and clinical studies show that activation of the MAP kinase pathway is associated with a reduction in the tumor infiltrating lymphocytes, and when we use the MEK inhibitor in combination with the anti-PDL1, it’s actually synergistic in the clinical model, which led us to conduct this particular trial. Right now…

Geneoscopy: Evaluating the Efficacy of a Non-Invasive Colorectal Cancer Screening Test: Findings from the CRC-PREVENT Phase 3 Trial Dr. David Lieberman By David Lieberman, MD The idea was to evaluate the efficacy of this Geneoscopy test to screen individuals age 45 and older for colorectal cancer. So, the basic principles of the study were that patients used the “Geneoscopy test”, that could be performed at home, to collect a stool-based diagnostic test. They were sent by express delivery and then to a laboratory, where they were analyzed. And then a key element of this study was that these patients…

Adipocyte Vaccine: Presents Promising Results for Patients with Breast Cancer at SABCS 2022 Nora Disis MD By Nora Disis, MD Obesity is a major problem and a major cause of cancer, and there’s a particular type of obesity called inflammatory obesity where patients develop metabolic dysfunction. This dysfunction is really mediated or caused by immune cells and the type of immune cells it’s caused by are CD8 T-cells. The CD8 T-cells begin to recognize immunogenic proteins in fat, and they proliferate and compete for limited resources in the body fat. They become dysfunctional, and this is one of the ways…

AI Risk Assessment: Sybil A Reliable Deep Learning Model for Predicting Future Lung Cancer Risk Dr. Florian Fintelmann By Florian Fintelmann, MD Sybil has not been used in other disease states. It was specifically developed to aid with the detection of lung cancer on low-dose chest CT, and those are chest CT exams that are performed specifically for lung cancer screenings, so all the data (sets) used to train, develop, tune, and test it were from low-dose chest CTs obtained specifically for lung cancer screening. Could you please explain to our viewers why Sybil has been chosen in this trial…

Antibody-Drug Conjugate Advancements for Breast Cancer Treatment: Updates from SABCS 2022 by Leif Ellisen MD By Leif Ellisen, MD So antibody drug conjugates, or as I’ll refer to them, ADCs are a really important new class of drugs. They’re very complicated structure in that they have three distinct components. One is an antibody that binds to a target on the surface of the tumor cell. That antibody is linked or conjugated to what we call a “cytotoxic payload,” typically a chemotherapy like drug, and when it’s linked to the antibody, that chemotherapy drug is carried into the cell. When the…

Invasive Lobular Breast Cancer: Steffi Oesterreich Shares Insightful Learning Sessions Exploring ILBC at SABCS 2022 By Steffi Oesterreich, PhD So, I was very excited about increasing attention to special subtypes of breast cancer. There was actually a unique session, an educational session called Challenging Types of Breast Cancer: Lobular/Pleomorphic, and I was very excited because invasive lobular breast cancer, which affects approximately 10 to 15% of all breast cancers, received quite a bit of attention there. I think in prior years that didn’t happen so much here at the San Antonio Breast Cancer Symposium (SABCS), so this was really…

Binimetinib: Combination Insights on the Treatment Strategy of Breast Cancer from SABCS 2022 Saranya Chumsri MD By Saranya Chumsri, MD This particular study is a phase 1/2 trial of Pembrolizumab in combination with Binimetinib (brand name MEKTOVI), which is a MEK inhibitor. So previous preclinical and clinical studies show that activation of the MAP kinase pathway is associated with a reduction in the tumor infiltrating lymphocytes, and when we use the MEK inhibitor in combination with the anti-PDL1, it’s actually synergistic in the clinical model, which led us to conduct this particular trial. Right now the current standard of…

The Significance of ctDNA in Predicting Recurrence and Delaying Progression in Breast Cancer Patients Mridula George MD By Mridula George, MD Breast cancer is a complex disease that requires a timely and accurate diagnosis, appropriate treatment, and close monitoring of disease progression. Despite the advances in diagnostic and treatment modalities, disease recurrence and progression remain a significant concern for breast cancer patients. Therefore, identifying reliable biomarkers that can predict disease recurrence and monitor disease progression is crucial for improving patient outcomes. Cell-free circulating tumor DNA (ctDNA) has emerged as a promising biomarker in breast cancer. ctDNA is released into the…

iFrame is not supported! Geneoscopy: Evaluating the Efficacy of a Non-Invasive Colorectal Cancer Screening Test: Findings from the CRC-PREVENT Phase 3 Trial Dr. David Lieberman By David Lieberman, MD The idea was to evaluate the efficacy of this Geneoscopy test to screen individuals age 45 and older for colorectal cancer. So, the basic principles of the study were that patients used the “Geneoscopy test”, that could be performed at home, to collect a stool-based diagnostic test. They were sent by express delivery and then to a laboratory, where they were analyzed. And then a key element of this study…

iFrame is not supported! Adipocyte Vaccine: Presents Promising Results for Patients with Breast Cancer at SABCS 2022 Nora Disis MD By Nora Disis, MD Obesity is a major problem and a major cause of cancer, and there’s a particular type of obesity called inflammatory obesity where patients develop metabolic dysfunction. This dysfunction is really mediated or caused by immune cells and the type of immune cells it’s caused by are CD8 T-cells. The CD8 T-cells begin to recognize immunogenic proteins in fat, and they proliferate and compete for limited resources in the body fat. They become dysfunctional, and this is…

iFrame is not supported! AI Risk Assessment: Sybil A Reliable Deep Learning Model for Predicting Future Lung Cancer Risk Dr. Florian Fintelmann By Florian Fintelmann, MD Sybil has not been used in other disease states. It was specifically developed to aid with the detection of lung cancer on low-dose chest CT, and those are chest CT exams that are performed specifically for lung cancer screenings, so all the data (sets) used to train, develop, tune, and test it were from low-dose chest CTs obtained specifically for lung cancer screening. Could you please explain to our viewers why Sybil has been…

The Importance of ctDNA in Breast Cancer Diagnosis and Treatment Planning Mridula George MD By Mridula George, MD Breast cancer (e.g., metastatic breast cancer) is the most common cancer in women worldwide, and early detection and personalized treatment are crucial for improving patient outcomes. Recently, the use of circulating tumor DNA (ctDNA) has emerged as a promising tool for the diagnosis and treatment of breast cancer. Initially, ctDNA (circulating tumor DNA) was mainly used in the metastatic setting, where it helped clinicians monitor disease progression and identify the most effective treatments. However, with the development of more sensitive assays, ctDNA…

iFrame is not supported! The Significance of ctDNA in Predicting Recurrence and Delaying Progression in Breast Cancer Patients Mridula George MD By Mridula George, MD Breast cancer is a complex disease that requires a timely and accurate diagnosis, appropriate treatment, and close monitoring of disease progression. Despite the advances in diagnostic and treatment modalities, disease recurrence and progression remain a significant concern for breast cancer patients. Therefore, identifying reliable biomarkers that can predict disease recurrence and monitor disease progression is crucial for improving patient outcomes. Cell-free circulating tumor DNA (ctDNA) has emerged as a promising biomarker in breast cancer. ctDNA…

Geneoscopy: Evaluating the Efficacy of a Non-Invasive Colorectal Cancer Screening Test: Findings from the CRC-PREVENT Phase 3 Trial Dr. David Lieberman By David Lieberman, MD The idea was to evaluate the efficacy of this Geneoscopy test to screen individuals age 45 and older for colorectal cancer. So, the basic principles of the study were that patients used the “Geneoscopy test”, that could be performed at home, to collect a stool-based diagnostic test. They were sent by express delivery and then to a laboratory, where they were analyzed. And then a key element of this study was that these patients…

Adipocyte Vaccine: Presents Promising Results for Patients with Breast Cancer at SABCS 2022 Nora Disis MD By Nora Disis, MD Obesity is a major problem and a major cause of cancer, and there’s a particular type of obesity called inflammatory obesity where patients develop metabolic dysfunction. This dysfunction is really mediated or caused by immune cells and the type of immune cells it’s caused by are CD8 T-cells. The CD8 T-cells begin to recognize immunogenic proteins in fat, and they proliferate and compete for limited resources in the body fat. They become dysfunctional, and this is one of the ways…

Gemtuzumab Ozogamicin Enhances Outcomes in Intermediate Risk AML Patients Receiving Standard Induction Therapy: ASH 2022 Study Results Eunice Wang MD By Eunice Wang, MD So many patients who have acute myeloid leukemia receive treatment based on their prognostic classification, usually favorable, intermediate, or poor risk. So for patients with favorable risk and for patients with adverse risks the treatment regimens are clearly very straightforward. For patients (AML (Acute Myeloid Leukemia)) with intermediate risk, which represents about half of our nearly diagnosed patients who are fit and able to tolerate intensive chemotherapy, we give them a standard regimen 7+3. There is…

Lung Cancer Screening Program: Cedars-Sinai Implements a Streamlined Approach by Sara Ghandehari MD Sara Ghandehari, MD Cedars-Sinai is a non-profit hospital located in Los Angeles, California. They recently implemented a program aimed at increasing the frequency of lung cancer screening, which is currently very low. In this article, we will discuss Cedars-Sinai’s streamlined approach to lung cancer screening, the criteria used to identify eligible individuals, and how their program compares to other similar programs. According to Cedars-Sinai, the rate of lung cancer screening is very low. Nationally, only 6% of those who qualify for lung cancer screening are getting…

AI Risk Assessment: Sybil A Reliable Deep Learning Model for Predicting Future Lung Cancer Risk Dr. Florian Fintelmann By Florian Fintelmann, MD Sybil has not been used in other disease states. It was specifically developed to aid with the detection of lung cancer on low-dose chest CT, and those are chest CT exams that are performed specifically for lung cancer screenings, so all the data (sets) used to train, develop, tune, and test it were from low-dose chest CTs obtained specifically for lung cancer screening. Could you please explain to our viewers why Sybil has been chosen in this trial…

iFrame is not supported! The Importance of ctDNA in Breast Cancer Diagnosis and Treatment Planning Mridula George MD By Mridula George, MD Breast cancer (e.g., metastatic breast cancer) is the most common cancer in women worldwide, and early detection and personalized treatment are crucial for improving patient outcomes. Recently, the use of circulating tumor DNA (ctDNA) has emerged as a promising tool for the diagnosis and treatment of breast cancer. Initially, ctDNA (circulating tumor DNA) was mainly used in the metastatic setting, where it helped clinicians monitor disease progression and identify the most effective treatments. However, with the development of…

iFrame is not supported! Gemtuzumab Ozogamicin Enhances Outcomes in Intermediate Risk AML Patients Receiving Standard Induction Therapy: ASH 2022 Study Results Eunice Wang MD By Eunice Wang, MD So many patients who have acute myeloid leukemia receive treatment based on their prognostic classification, usually favorable, intermediate, or poor risk. So for patients with favorable risk and for patients with adverse risks the treatment regimens are clearly very straightforward. For patients (AML (Acute Myeloid Leukemia)) with intermediate risk, which represents about half of our nearly diagnosed patients who are fit and able to tolerate intensive chemotherapy, we give them a standard…

iFrame is not supported! Lung Cancer Screening Program: Cedars-Sinai Implements a Streamlined Approach by Sara Ghandehari MD Sara Ghandehari, MD Cedars-Sinai is a non-profit hospital located in Los Angeles, California. They recently implemented a program aimed at increasing the frequency of lung cancer screening, which is currently very low. In this article, we will discuss Cedars-Sinai’s streamlined approach to lung cancer screening, the criteria used to identify eligible individuals, and how their program compares to other similar programs. According to Cedars-Sinai, the rate of lung cancer screening is very low. Nationally, only 6% of those who qualify for lung…

Gemtuzumab Ozogamicin Enhances Outcomes in Intermediate Risk AML Patients Receiving Standard Induction Therapy: ASH 2022 Study Results Eunice Wang MD By Eunice Wang, MD So many patients who have acute myeloid leukemia receive treatment based on their prognostic classification, usually favorable, intermediate, or poor risk. So for patients with favorable risk and for patients with adverse risks the treatment regimens are clearly very straightforward. For patients (AML (Acute Myeloid Leukemia)) with intermediate risk, which represents about half of our nearly diagnosed patients who are fit and able to tolerate intensive chemotherapy, we give them a standard regimen 7+3. There is…

Lung Cancer Screening Program: Cedars-Sinai Implements a Streamlined Approach by Sara Ghandehari MD Sara Ghandehari, MD Cedars-Sinai is a non-profit hospital located in Los Angeles, California. They recently implemented a program aimed at increasing the frequency of lung cancer screening, which is currently very low. In this article, we will discuss Cedars-Sinai’s streamlined approach to lung cancer screening, the criteria used to identify eligible individuals, and how their program compares to other similar programs. According to Cedars-Sinai, the rate of lung cancer screening is very low. Nationally, only 6% of those who qualify for lung cancer screening are getting…

The Significance of ctDNA in Predicting Recurrence and Delaying Progression in Breast Cancer Patients Mridula George MD By Mridula George, MD Breast cancer is a complex disease that requires a timely and accurate diagnosis, appropriate treatment, and close monitoring of disease progression. Despite the advances in diagnostic and treatment modalities, disease recurrence and progression remain a significant concern for breast cancer patients. Therefore, identifying reliable biomarkers that can predict disease recurrence and monitor disease progression is crucial for improving patient outcomes. Cell-free circulating tumor DNA (ctDNA) has emerged as a promising biomarker in breast cancer. ctDNA is released into the…

The Importance of ctDNA in Breast Cancer Diagnosis and Treatment Planning Mridula George MD By Mridula George, MD Breast cancer (e.g., metastatic breast cancer) is the most common cancer in women worldwide, and early detection and personalized treatment are crucial for improving patient outcomes. Recently, the use of circulating tumor DNA (ctDNA) has emerged as a promising tool for the diagnosis and treatment of breast cancer. Initially, ctDNA (circulating tumor DNA) was mainly used in the metastatic setting, where it helped clinicians monitor disease progression and identify the most effective treatments. However, with the development of more sensitive assays, ctDNA…

Open Label Phase III TIGeR-PaC Interim Data Observes 6-Month Median Survival Benefit: RenovoGem (Intra-Arterial Gemcitabine) Versus IV Gemcitabine and Nab-paclitaxel for Pancreatic Cancer Treatment By Michael Pishvaian, MD, PhD Listen the to Audio Podcast: Stephanie Comello · David Lieberman, MD – Geneoscopy’s Colorectal Cancer Screening Test David Lieberman, MD – Geneoscopy’s Colorectal Cancer Screening Test Locally advanced pancreatic cancer has its own challenges because we’re really focused on trying to treat the tumor where it lies within the pancreas, while also treating the systemic micrometastatic disease that almost certainly is there. It’s also not usually a situation where we’re trying…

Elacestrant: FDA Grants Approval for Breast Cancer Treatment: Insights from Virginia Kaklamani By Virginia Kaklamani So after a patient’s cancer has progressed and and we’re talking about ER+ metastatic breast cancer in the first line setting, which we typically give a CDK4/6 inhibitor and endocrine therapy, we really don’t have a lot of good effective therapies. And the data that we’ve had since the use of CDK4/6 inhibitors has suggested a median PFS (progression-free survival) of anywhere between 3-5 months, with subsequent endocrine therapies. So this is why this field is extremely important in trying to find effective endocrine therapies…

iFrame is not supported! Elacestrant: FDA Grants Approval for Breast Cancer Treatment: Insights from Virginia Kaklamani By Virginia Kaklamani So after a patient’s cancer has progressed and and we’re talking about ER+ metastatic breast cancer in the first line setting, which we typically give a CDK4/6 inhibitor and endocrine therapy, we really don’t have a lot of good effective therapies. And the data that we’ve had since the use of CDK4/6 inhibitors has suggested a median PFS (progression-free survival) of anywhere between 3-5 months, with subsequent endocrine therapies. So this is why this field is extremely important in trying to…

FLEX Trial Breast Cancer: SABCS 2022 Mehran Habnibi MD Looking at Gene Mutations By Mehran Habibi, MD, MBA The new adjuvant hormone therapy and to treat the breast cancers that are estrogen positive in the US is not really something that we do a lot. So we do a lot of new adjuvant chemotherapies, but the new adjuvant hormone therapy has not really picked up. One of the reasons is that it takes quite some time for the hormone therapy to work and start to shrink the tumor to have a clinical response, around 3 months, sometimes 6 months or…

iFrame is not supported! FLEX Trial Breast Cancer: SABCS 2022 Mehran Habnibi MD Looking at Gene Mutations By Mehran Habibi, MD, MBA The new adjuvant hormone therapy and to treat the breast cancers that are estrogen positive in the US is not really something that we do a lot. So we do a lot of new adjuvant chemotherapies, but the new adjuvant hormone therapy has not really picked up. One of the reasons is that it takes quite some time for the hormone therapy to work and start to shrink the tumor to have a clinical response, around 3 months,…

Elacestrant: FDA Grants Approval for Breast Cancer Treatment: Insights from Virginia Kaklamani By Virginia Kaklamani So after a patient’s cancer has progressed and and we’re talking about ER+ metastatic breast cancer in the first line setting, which we typically give a CDK4/6 inhibitor and endocrine therapy, we really don’t have a lot of good effective therapies. And the data that we’ve had since the use of CDK4/6 inhibitors has suggested a median PFS (progression-free survival) of anywhere between 3-5 months, with subsequent endocrine therapies. So this is why this field is extremely important in trying to find effective endocrine therapies…

FLEX Trial Breast Cancer: SABCS 2022 Mehran Habnibi MD Looking at Gene Mutations By Mehran Habibi, MD, MBA The new adjuvant hormone therapy and to treat the breast cancers that are estrogen positive in the US is not really something that we do a lot. So we do a lot of new adjuvant chemotherapies, but the new adjuvant hormone therapy has not really picked up. One of the reasons is that it takes quite some time for the hormone therapy to work and start to shrink the tumor to have a clinical response, around 3 months, sometimes 6 months or…

Sacituzumab Govitecan: SABCS 2022 Sara Tolaney vs Chemo TROPiCS-02 By Sara Tolaney, MD What were the patient-reported outcomes from the TROPiCS-02 trial? So this year at San Antonio, we saw data from TROPiCS-02. This was a randomized phase 3 study that compared Sacituzumab Govitecan (SG), which is a novel antibody drug conjugate, to standard of care chemotherapy in patients with metastatic hormone receptor positive breast cancer. We’d seen results from this trial previously, initially at ASCO, we saw data regarding progression-free survival (PFS), demonstrating that Sacituzumab Govitecan (SG) led to an improvement in progression-free survival compared to chemotherapy in…

iFrame is not supported! Sacituzumab Govitecan: SABCS 2022 Sara Tolaney vs Chemo TROPiCS-02 By Sara Tolaney, MD What were the patient-reported outcomes from the TROPiCS-02 trial? So this year at San Antonio, we saw data from TROPiCS-02. This was a randomized phase 3 study that compared Sacituzumab Govitecan (SG), which is a novel antibody drug conjugate, to standard of care chemotherapy in patients with metastatic hormone receptor positive breast cancer. We’d seen results from this trial previously, initially at ASCO, we saw data regarding progression-free survival (PFS), demonstrating that Sacituzumab Govitecan (SG) led to an improvement in progression-free survival…

Sacituzumab Govitecan: SABCS 2022 Sara Tolaney vs Chemo TROPiCS-02 By Sara Tolaney, MD What were the patient-reported outcomes from the TROPiCS-02 trial? So this year at San Antonio, we saw data from TROPiCS-02. This was a randomized phase 3 study that compared Sacituzumab Govitecan (SG), which is a novel antibody drug conjugate, to standard of care chemotherapy in patients with metastatic hormone receptor positive breast cancer. We’d seen results from this trial previously, initially at ASCO, we saw data regarding progression-free survival (PFS), demonstrating that Sacituzumab Govitecan (SG) led to an improvement in progression-free survival compared to chemotherapy in…

Heterogeneity: SABCS 2022 Adrian Lee PhD Highlighted Research in Transcriptomics By Professor Adrian Lee How can heterogeneity in breast cancer metastasis highlighted research in transcriptomics help patients? So this year at SABCS (San Antonio Breast Cancer Symposium) we learned a lot about the heterogeneity of breast cancer. It’s helped us to understand the heterogeneity, and there was lots of talks and posters on new techniques and allow us to unravel the molecular features that have gone wrong in breast cancer and that’s helping us then direct therapies to them, and many of the clinical trials are using these new targets…

iFrame is not supported! Heterogeneity: SABCS 2022 Adrian Lee PhD Highlighted Research in Transcriptomics By Professor Adrian Lee How can heterogeneity in breast cancer metastasis highlighted research in transcriptomics help patients? So this year at SABCS (San Antonio Breast Cancer Symposium) we learned a lot about the heterogeneity of breast cancer. It’s helped us to understand the heterogeneity, and there was lots of talks and posters on new techniques and allow us to unravel the molecular features that have gone wrong in breast cancer and that’s helping us then direct therapies to them, and many of the clinical trials are…

Heterogeneity: SABCS 2022 Adrian Lee PhD Highlighted Research in Transcriptomics By Professor Adrian Lee How can heterogeneity in breast cancer metastasis highlighted research in transcriptomics help patients? So this year at SABCS (San Antonio Breast Cancer Symposium) we learned a lot about the heterogeneity of breast cancer. It’s helped us to understand the heterogeneity, and there was lots of talks and posters on new techniques and allow us to unravel the molecular features that have gone wrong in breast cancer and that’s helping us then direct therapies to them, and many of the clinical trials are using these new targets…

Brentuximab: ASH 2022 Dr. Mitul Gandhi Updated Efficacy and Safety Results By Mitul Gandhi, MD What were the results of the safety and efficacy of Brentuximab brand name ADCETRIS, in patients with Hodgkin Lymphoma? So this is a multi-center, multi-part study. Taking patients in this particular part B, evaluating patients with stage 2 bulky hodgkin’s lymphoma and stage 3 and 4 hodgkin lymphoma. The existing standard of care represents a combination of ABVD Adriamycin, Bleomycin, Vinblastine, Dacarbazine, often with omission of Bleomycin after PET stratification after cycle 2. Along with the newer standard of care based on the ECHELON-1 data…

iFrame is not supported! Brentuximab: ASH 2022 Dr. Mitul Gandhi Updated Efficacy and Safety Results By Mitul Gandhi, MD What were the results of the safety and efficacy of Brentuximab brand name ADCETRIS, in patients with Hodgkin Lymphoma? So this is a multi-center, multi-part study. Taking patients in this particular part B, evaluating patients with stage 2 bulky hodgkin’s lymphoma and stage 3 and 4 hodgkin lymphoma. The existing standard of care represents a combination of ABVD Adriamycin, Bleomycin, Vinblastine, Dacarbazine, often with omission of Bleomycin after PET stratification after cycle 2. Along with the newer standard of care based…

Brentuximab: ASH 2022 Dr. Mitul Gandhi Updated Efficacy and Safety Results By Mitul Gandhi, MD What were the results of the safety and efficacy of Brentuximab brand name ADCETRIS, in patients with Hodgkin Lymphoma? So this is a multi-center, multi-part study. Taking patients in this particular part B, evaluating patients with stage 2 bulky hodgkin’s lymphoma and stage 3 and 4 hodgkin lymphoma. The existing standard of care represents a combination of ABVD Adriamycin, Bleomycin, Vinblastine, Dacarbazine, often with omission of Bleomycin after PET stratification after cycle 2. Along with the newer standard of care based on the ECHELON-1 data…

Odronextamab: ASH 2022 Won Seog Kim MD Prespecified Analysis ELM-2 in DLBCL By Won Seog Kim, MD How can Odronextamab help patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)? I presented here the interim analysis data for the next one, monotherapy, in patients with relapsed refractory DLBCL, in general, in patients who had the prior two or more lines of treatment. The outcome is quite disappointing in this Odronextamab clinical trial. The expected survivor was less than several months, and with the cytotoxic agent, we cannot have good until now. So here we, I’m presenting the other next monotherapy…

iFrame is not supported! Odronextamab: ASH 2022 Won Seog Kim MD Prespecified Analysis ELM-2 in DLBCL By Won Seog Kim, MD How can Odronextamab help patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)? I presented here the interim analysis data for the next one, monotherapy, in patients with relapsed refractory DLBCL, in general, in patients who had the prior two or more lines of treatment. The outcome is quite disappointing in this Odronextamab clinical trial. The expected survivor was less than several months, and with the cytotoxic agent, we cannot have good until now. So here we, I’m presenting…

Odronextamab: ASH 2022 Won Seog Kim MD Prespecified Analysis ELM-2 in DLBCL By Won Seog Kim, MD How can Odronextamab help patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)? I presented here the interim analysis data for the next one, monotherapy, in patients with relapsed refractory DLBCL, in general, in patients who had the prior two or more lines of treatment. The outcome is quite disappointing in this Odronextamab clinical trial. The expected survivor was less than several months, and with the cytotoxic agent, we cannot have good until now. So here we, I’m presenting the other next monotherapy…

Phase 3 ITHACA Study Results: Latest Insights on Isatuximab presented from ASH 2022 discussed by Dr. Irene Ghobrial from Dana-Farber Cancer Institute Isatuximab: ASH 2022 Irene Ghobrial Phase 3 Ithaca Study We presented in the American Society of Hematology (ASH). Several abstracts related to MGUS and smoldering multiple myeloma. Some of them about risk stratification, who should be treated for smoldering myeloma because we know that many people are diagnosed with MGUS and smoldering myeloma… Read Article Watch Video Listen to Audio MRD: ASH 2022 Ben Derman the MRD2STOP Guide The study that we have conducted or we’re currently…

Pembrolizumab’s approval in this setting does not mean clinical value for Adjuvant Therapy for Resected NSCLC By Jack West, MD Hi, I’m Dr. Jack West, and I’m a thoracic oncologist and associate professor at the City of Hope Comprehensive Cancer Center in the Los Angeles area. I wanted to take a minute to talk about the very recent FDA approval of pembrolizumab in the adjuvant setting for to treat patients with resected stage 1B to stage IIIA non-small cell lung cancer, and specifically how much or how little this FDA approval should translate to clinical use, or should we presume…

iFrame is not supported! Pembrolizumab’s approval in this setting does not mean clinical value for Adjuvant Therapy for Resected NSCLC By Jack West, MD Hi, I’m Dr. Jack West, and I’m a thoracic oncologist and associate professor at the City of Hope Comprehensive Cancer Center in the Los Angeles area. I wanted to take a minute to talk about the very recent FDA approval of pembrolizumab in the adjuvant setting for to treat patients with resected stage 1B to stage IIIA non-small cell lung cancer, and specifically how much or how little this FDA approval should translate to clinical use,…

Pembrolizumab’s approval in this setting does not mean clinical value for Adjuvant Therapy for Resected NSCLC By Jack West, MD Hi, I’m Dr. Jack West, and I’m a thoracic oncologist and associate professor at the City of Hope Comprehensive Cancer Center in the Los Angeles area. I wanted to take a minute to talk about the very recent FDA approval of pembrolizumab in the adjuvant setting for to treat patients with resected stage 1B to stage IIIA non-small cell lung cancer, and specifically how much or how little this FDA approval should translate to clinical use, or should we presume…

2023 ASH BCMA & Multiple Myeloma Updates with Slides by: Lisa Lee, MD – Assistant Professor — Division of Hematology-Oncology, Department of Medicine, UCI School of Medicine I wanna give you a quick update of the myeloma abstracts at ASH. And inevitably it’s gonna end up kind of focusing on the evolving saga over immunotherapies, because that’s the way that the field is heading. I have no conflicts of interest. So for those of you who treat myeloma, you know that we’re still plagued by this paradigm wherein we can’t tell patients that there’s a cure for their disease. Each subsequent…

ASH Meeting 2022 – Hematopoietic Stem Cell Transplantation with Tacrolimus Updates By Stefan O. Ciurea, MD from UCI Health So I talked about a couple of abstracts from ASH presented ASH this year. And one of the most important probably was the late breaking abstract 4 with post transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil GVHD Prophylaxis randomized to tacrolimus (Tac) plus methotrexate (MTX) for patients with hematologic malignancies, ongoing transplantation with a reduced intensity condition regimen. This was a BMT CTN study 1703, and this study showed that GRFS GVHD-free relapse-free survival was significantly better. With Post-Transplant Cyclophosphamide, Tacrolimus, and…

What ASH abstracts stood out to you most in multiple myeloma? By Lisa X. Lee, MD from UCI Health At ASH this year, it was all about immunotherapy for multiple myeloma. This year’s ASH came on the heels of two major approvals for BCMA directed CAR T, as well as our first approved BCMA bispecific. And I think, the question for people who treat myeloma is how can we improve upon these approved therapies? There were a lot of exciting abstracts and oral presentations on optimizing T-cell therapy, the cellular product itself. There are also interesting presentations on the sequencing…

Myelodysplastic Syndromes Treatment Update for 2023 By Deepa Jeyakumar, MD from UCI Health I think what’s very exciting is that in the past year we’ve seen multiple different agents that are available for patients, giving them more options for these difficult to treat diseases in low risk MDs. We have seen the initial results. With a telomerase inhibitor, which will hopefully prove beneficial in patients with lower risk MDs and complete transfusion independence, patients can spend less time in the infusion centers getting blood transfusions and more time outliving their lives. In higher risk MDs, there are multiple different options…

Zanubrutinib compared to ibrutinib in chronic lymphocytic leukemia By Elizabeth Brém, MD from UCI Health We focused basically on two major as abstracts from ASH this year. One of which was a late breaking abstract called the Aspen Study, which was Zanubrutinib versus Ibrutinib in treatment of CLL, which showed a progression-free survival benefit for Zanubrutinib, and actually led to a recent FDA approval for Zanubrutinib for treatment of CLL. And we also talked about the triangle study, which had been presented at the plenary, looking at whether or not we should incorporate Ibrutinib into our standard of care…

Women with recurrent miscarriage were treated with low molecular weight heparin versus usual pregnancy care By Zahra Pakbaz, MD from UCI Health Today was mainly MOASC Hematology Spotlight, and my session was about nonmalignant hematology. So I tried to summarize some of the abstracts which were presented at ASH. But because of, it’s a garden variety of diseases are all bunched up in non-cancer blood disorders. So I decided to pick the two benign hematology late breaking abstracts. One was about PNH (Paroxysmal nocturnal hemoglobinuria) and the new development of an overall medication complement inhibitor and B factor, B inhibitor,…

ASH Meeting 2022 – Hematopoietic Stem Cell Transplantation with Tacrolimus UpdatesBy: Stefan O. Ciurea, MD – Director, Hematopoietic Stem Cell Transplantation and Cellular Therapy Program University of California IrvineI was asked to talk about ab ASH updates and I selected 13 abstracts. I’m gonna go through them very fast if we’re already late. I have about 50 slides, first abstract I wanna talk about is this late breaking abstract, which is in fact first results from a randomized phase three trial done by BMT CTN. comparing two methods of GVHD prophylaxis with post transplantation, cyclophosphamide, Tacrolimus, MMF versus tacrolimus, methotrexate,…

iFrame is not supported! Inotuzumab and MRD Understanding the Importance of Targeted Therapy in Cancer Treatment Summarized from Van Huynh, MD’s video on MRD: 2023 ASH ALL Inotuzumab Update [Slides] – MOASC Hematological malignancies like acute lymphoblastic leukaemia (AML) are diseases that affects millions of people worldwide, and it is essential to have effective treatments that can target the specific type of cancer and its underlying genetic mutations. Targeted therapy is a type of cancer treatment that aims to inhibit the specific genetic mutations or proteins that drive the growth of cancer cells. In this article, we will explore the…

Intra-arterial Versus Intravenous Gemcitabine Administration: PK Substudy within the Phase III TIGeR-PaC Clinical Trial in Locally Advanced Pancreatic Cancer By Paula Novelli, MD At this year’s ASCO GI Symposium (in January 2023), our team presented intra-arterial gemcitabine versus intravenous gemcitabine PK substudy data within the RenovoRx TIGeR-PaC Phase III clinical trial. In a cohort of 13 patients, 7 patients were in the intra-arterial arm and 6 patients, the intravenous arm. Despite a 30% increased concentration in infusion in the intra-arterial arm, there was an average of 50% reduction in systemic drug exposure which is significant based on the entire concept…

iFrame is not supported! Intra-arterial Versus Intravenous Gemcitabine Administration: PK Substudy within the Phase III TIGeR-PaC Clinical Trial in Locally Advanced Pancreatic Cancer By Paula Novelli, MD At this year’s ASCO GI Symposium (in January 2023), our team presented intra-arterial gemcitabine versus intravenous gemcitabine PK substudy data within the RenovoRx TIGeR-PaC Phase III clinical trial. In a cohort of 13 patients, 7 patients were in the intra-arterial arm and 6 patients, the intravenous arm. Despite a 30% increased concentration in infusion in the intra-arterial arm, there was an average of 50% reduction in systemic drug exposure which is significant based…

Intra-arterial Versus Intravenous Gemcitabine Administration: PK Substudy within the Phase III TIGeR-PaC Clinical Trial in Locally Advanced Pancreatic Cancer By Paula Novelli, MD At this year’s ASCO GI Symposium (in January 2023), our team presented intra-arterial gemcitabine versus intravenous gemcitabine PK substudy data within the RenovoRx TIGeR-PaC Phase III clinical trial. In a cohort of 13 patients, 7 patients were in the intra-arterial arm and 6 patients, the intravenous arm. Despite a 30% increased concentration in infusion in the intra-arterial arm, there was an average of 50% reduction in systemic drug exposure which is significant based on the entire concept…

Myelodysplastic Syndromes Treatment Update for 2023 ASH AML Inotuzumab Update [Slides] – Kiran Naqvi, MD MOASC By Kiran Naqvi, MD So today my talk was mainly highlighting the ASH abstracts or ash highlights of 2022. And I had the pleasure of presenting several abstracts, actually all of them, which I felt were really important. But some of the few that I wanted to mention that I think are important now is that we have really good experience with chemotherapy in our younger patients. And with the combination of Cytarabine, with Idarubicin or Anthracycline. But now we need to talk more…

MRD: Inotuzumab, GMALL, Ponatinib & Blinatumomab ASH Updates in Acute Lymphoblastic Leukemia/Immunotherapy By Van Huynh, MD Today I spoke at MOASC (Medical Oncology Association of Southern California), and the focus was on acute lymphoblastic leukemia, or ALL, along with any new updates on immunotherapy in this population. Did anything stand out to you about these clinical trials? So I presented on three separate studies, and I think the general theme was that it acknowledged that the overall survival rate for adults with ALL (acute lymphoblastic leukemia) has historically been poor. But there have been many. There have been…

Myelodysplastic Syndromes Treatment Update for 2023 So briefly with regard to myelodysplastic syndromes MDS, I just wanted to discuss some of the proposed changes to classification, as well as some of the changes and updates and low-risk myelodysplastic syndromes, as well as high-risk myelodysplastic syndromes. So in June of 2022, the molecular international prognostic score was proposed. This has been long awaited based. Previously, we were using the I P S R. The problem with that system is that it didn’t include some of the important molecular findings that re leukemia were affecting outcome. So the purpose of the update…

Inotuzumab, GMALL, Ponatinib & Blinatumomab ASH Updates in Acute Lymphoblastic Leukemia By Van Huynh, MD Updates in acute lymphoblastic leukemia that was presented at ASH in New Orleans. So I think there were so many great talks. There were so many great talks and I decided I would focus on just three and really go into the details of each of those talks. I think there’s a theme there. So the first will be The trial by the gm, o l, which is the outcome of patients with newly diagnosed pH negative ALL treated according to a pediatric based regimen.…

Zanubrutinib compared to ibrutinib in chronic lymphocytic leukemia So I’m gonna start with chronic lymphocytic leukemia. And as part of late-breaking abstracts, we got this study which was zanubrutinib compared to ibrutinib before chronic lymphocytic leukemia.Relatively straightforward study design. These were previously treated patients, so one prior systemic therapy, measurable disease, no prior BTK inhibitors, and they were randomized one to one to zanubrutinib or ibrutinib. The primary endpoint was progression-free survival and treatment continued until progression or toxicity.And this was obviously a randomized study, so it was relatively balanced. The median age was about right for chronic lymphocytic leukemia…

2023 ASH Pregnancy Update Slides Etavopivat treatment Low molecular weight heparin versus a standard pregnancy care for women with recurrent miscarriage Okay, so this first abstract let’s talk about low molecular weight heparin versus a standard pregnancy care for women with recurrent miscarriage age and inherited thrombophilia. ALIFE2, which was an open-label phase three randomized control trial. As studies have shown an association between re. Carriages and inherited thrombophilia. And usually we just put the patient on ox if they have miscarriages, plus the proven thrombophilia. And then we go until the end of the pregnancy with ox. And…

2023 ASH AML Updates [Slides] – Kiran Naqvi MD – MOASC Acute myeloid leukemia updates from our recent ASH from 2022 By Kiran Naqvi, MD Acute myeloid leukemia. These are the updates from our recent ASH from 2022 Acute myeloid leukemia. These are the updates from our recent ASH from 2022. So moving on. The first abstract that I wanted to talk about was an acute promyelocytic leukemia standard risk not high risk where patient, this is a Chinese study, sorry. And. What they did was they compared ECTRA in combination with an oral formation of arsenic known as RGA Indigo.…

Liso-cel: ASH 2022 Jeremy Abramson vs. SOC SCT and ASCT in RR LBCL By Jeremy Abramson, MD What did the phase 3 Transform study show in patients with relapsed or refractory large B-cell lymphoma (LBCL)? So with this ASH (American Society of Hematology) meeting, I was honored to present the primary analysis of the Transform trial, which is a randomized phase 3 trial comparing Lisocabtagene Maraleucel (liso-cel), an anti CD19 CAR T-cell product, with the standard of care as second line therapy in patients with relapsed or refractory large B-cell lymphomas. We specifically looked at patients with primary refractory disease…

iFrame is not supported! Liso-cel: ASH 2022 Jeremy Abramson vs. SOC SCT and ASCT in RR LBCL By Jeremy Abramson, MD What did the phase 3 Transform study show in patients with relapsed or refractory large B-cell lymphoma (LBCL)? So with this ASH (American Society of Hematology) meeting, I was honored to present the primary analysis of the Transform trial, which is a randomized phase 3 trial comparing Lisocabtagene Maraleucel (liso-cel), an anti CD19 CAR T-cell product, with the standard of care as second line therapy in patients with relapsed or refractory large B-cell lymphomas. We specifically looked at patients…

Liso-cel: ASH 2022 Jeremy Abramson vs. SOC SCT and ASCT in RR LBCL By Jeremy Abramson, MD What did the phase 3 Transform study show in patients with relapsed or refractory large B-cell lymphoma (LBCL)? So with this ASH (American Society of Hematology) meeting, I was honored to present the primary analysis of the Transform trial, which is a randomized phase 3 trial comparing Lisocabtagene Maraleucel (liso-cel), an anti CD19 CAR T-cell product, with the standard of care as second line therapy in patients with relapsed or refractory large B-cell lymphomas. We specifically looked at patients with primary refractory disease…

MRD: ASH 2022 Ben Derman the MRD2STOP Guide By Ben Derman, MD How can the MRD2STOP guide help patients with MRD? So the study that we have conducted or we’re currently conducting is really a prospective trial. And what we’re trying to do is take patients who have shown to have a durable, deep response to treatment for their myeloma and who are on maintenance therapy and see if they are able to stop their treatment, and then what happens after that happens. And so we’re really relying on MRD (minimal residual disease) testing or MRD (minimal residual disease) technology.…

iFrame is not supported! MRD: ASH 2022 Ben Derman the MRD2STOP Guide By Ben Derman, MD How can the MRD2STOP guide help patients with MRD? So the study that we have conducted or we’re currently conducting is really a prospective trial. And what we’re trying to do is take patients who have shown to have a durable, deep response to treatment for their myeloma and who are on maintenance therapy and see if they are able to stop their treatment, and then what happens after that happens. And so we’re really relying on MRD (minimal residual disease) testing or MRD…

MRD: ASH 2022 Ben Derman the MRD2STOP Guide By Ben Derman, MD How can the MRD2STOP guide help patients with MRD? So the study that we have conducted or we’re currently conducting is really a prospective trial. And what we’re trying to do is take patients who have shown to have a durable, deep response to treatment for their myeloma and who are on maintenance therapy and see if they are able to stop their treatment, and then what happens after that happens. And so we’re really relying on MRD (minimal residual disease) testing or MRD (minimal residual disease) technology.…

Isatuximab: ASH 2022 Irene Ghobrial Phase 3 Ithaca Study By Irene Ghobrial, MD What does the Ithaca clinical trials updated safety run-in results show for patients with High-Risk Smoldering Multiple Myeloma? We presented in the American Society of Hematology (ASH). Several abstracts related to MGUS and smoldering multiple myeloma. Some of them about risk stratification, who should be treated for smoldering myeloma because we know that many people are diagnosed with MGUS and smoldering myeloma, but not everyone will to active disease. So we need to be very selective in understanding better who should be treated for the disease and…

iFrame is not supported! Isatuximab: ASH 2022 Irene Ghobrial Phase 3 Ithaca Study By Irene Ghobrial, MD What does the Ithaca clinical trials updated safety run-in results show for patients with High-Risk Smoldering Multiple Myeloma? We presented in the American Society of Hematology (ASH). Several abstracts related to MGUS and smoldering multiple myeloma. Some of them about risk stratification, who should be treated for smoldering myeloma because we know that many people are diagnosed with MGUS and smoldering myeloma, but not everyone will to active disease. So we need to be very selective in understanding better who should be treated…

Isatuximab: ASH 2022 Irene Ghobrial Phase 3 Ithaca Study By Irene Ghobrial, MD What does the Ithaca clinical trials updated safety run-in results show for patients with High-Risk Smoldering Multiple Myeloma? We presented in the American Society of Hematology (ASH). Several abstracts related to MGUS and smoldering multiple myeloma. Some of them about risk stratification, who should be treated for smoldering myeloma because we know that many people are diagnosed with MGUS and smoldering myeloma, but not everyone will to active disease. So we need to be very selective in understanding better who should be treated for the disease and…

Emerging BTK inhibitors are positioned to change the landscape and impact your chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) treatment plans. Are you ready to incorporate these emerging therapies into your treatment plans? Dr. Sameer Parikh discusses these emerging BTK inhibitors for CLL / SLL, how they differ from current approaches, and future opportunities to introduce these therapies into your clinical decisions. Hear a patient case and the question and answer portion from this visiting lecture series. This activity also includes downloadable slides from the series to improve care for your patients with CLL/SLL. To claim credit: https://www.achlcme.org/btk-inhibitors-cll-sll-onctube

Anti-CD38: ASH 2022 Joshua Richter Treatment Patterns and Pt Outcomes By Joshua Richter, MD What is a Anti-CD38? And How can Anti-CD38 help patients with Relapsed/Refractory Multiple Myeloma (RRMM)? This study that we presented at this year’s ASH (American Society of Hematology) meeting was entitled, Enduring Responses After One Year Fixed Duration Cevostamab Therapy in Patients With Relapsed And Refractory Of Multiple Myeloma Early Experience From A Phase 1 study. Now, the bispecific antibodies are an exciting new field in myeloma, with the recent approval of Teclistamab and the recent filing of Talquetamab we recognize that they’re gonna be…

iFrame is not supported! Anti-CD38: ASH 2022 Joshua Richter Treatment Patterns and Pt Outcomes By Joshua Richter, MD What is a Anti-CD38? And How can Anti-CD38 help patients with Relapsed/Refractory Multiple Myeloma (RRMM)? This study that we presented at this year’s ASH (American Society of Hematology) meeting was entitled, Enduring Responses After One Year Fixed Duration Cevostamab Therapy in Patients With Relapsed And Refractory Of Multiple Myeloma Early Experience From A Phase 1 study. Now, the bispecific antibodies are an exciting new field in myeloma, with the recent approval of Teclistamab and the recent filing of Talquetamab we recognize…

Anti-CD38: ASH 2022 Joshua Richter Treatment Patterns and Pt Outcomes By Joshua Richter, MD What is a Anti-CD38? And How can Anti-CD38 help patients with Relapsed/Refractory Multiple Myeloma (RRMM)? This study that we presented at this year’s ASH (American Society of Hematology) meeting was entitled, Enduring Responses After One Year Fixed Duration Cevostamab Therapy in Patients With Relapsed And Refractory Of Multiple Myeloma Early Experience From A Phase 1 study. Now, the bispecific antibodies are an exciting new field in myeloma, with the recent approval of Teclistamab and the recent filing of Talquetamab we recognize that they’re gonna be…

Pembro: ASH 2022 Craig Sauter After auto-SCT in T-Cell NHL By Craig Sauter, MD How does Pembrolizumab (MK-3475), also known as Pembro, after Autologous Stem Cell Transplantation in Patients with T-Cell Non-Hodgkin Lymphoma help? So this was a multi-side phase 2 single armed study. Originally designed with multiple cohorts looking at the role of Pembrolizumab (Pembro) maintenance, following high dose chemotherapy and autologous stem cell transplant in consolidation for various lymphomas. The abstract presented at ASH was cohort C, which is looking specifically at the patient’s proceeding to consolidative autonomous transplant for peripheral T-cell lymphomas. So this was a…

iFrame is not supported! Pembro: ASH 2022 Craig Sauter After auto-SCT in T-Cell NHL By Craig Sauter, MD How does Pembrolizumab (MK-3475), also known as Pembro, after Autologous Stem Cell Transplantation in Patients with T-Cell Non-Hodgkin Lymphoma help? So this was a multi-side phase 2 single armed study. Originally designed with multiple cohorts looking at the role of Pembrolizumab (Pembro) maintenance, following high dose chemotherapy and autologous stem cell transplant in consolidation for various lymphomas. The abstract presented at ASH was cohort C, which is looking specifically at the patient’s proceeding to consolidative autonomous transplant for peripheral T-cell lymphomas.…

Pembro: ASH 2022 Craig Sauter After auto-SCT in T-Cell NHL By Craig Sauter, MD How does Pembrolizumab (MK-3475), also known as Pembro, after Autologous Stem Cell Transplantation in Patients with T-Cell Non-Hodgkin Lymphoma help? So this was a multi-side phase 2 single armed study. Originally designed with multiple cohorts looking at the role of Pembrolizumab (Pembro) maintenance, following high dose chemotherapy and autologous stem cell transplant in consolidation for various lymphomas. The abstract presented at ASH was cohort C, which is looking specifically at the patient’s proceeding to consolidative autonomous transplant for peripheral T-cell lymphomas. So this was a…

MPN: ASH 2022 Abdulraheem Yacoub Add-on of Parsaclisib By Abdulraheem Yacoub, MD What were the results of the MPN (myeloproliferative neoplasm) Study of the add-on of Parsaclisib to Ruxolitinib therapy? At the American Society of Hematology (ASH) 2022 in New Orleans, I had the opportunity to present the final safety and efficacy results of the add-on Parsaclisib study in patients with myelofibrosis and suboptimal response. This is the final results of a phase 2 study. Ruxolitinib has been approved for myelofibrosis, for clinical benefits. That includes splenic reduction, symptom improvement, and survival advantage. However, some patients manifest a suboptimal…

iFrame is not supported! MPN: ASH 2022 Abdulraheem Yacoub Add-on of Parsaclisib By Abdulraheem Yacoub, MD What were the results of the MPN (myeloproliferative neoplasm) Study of the add-on of Parsaclisib to Ruxolitinib therapy? At the American Society of Hematology (ASH) 2022 in New Orleans, I had the opportunity to present the final safety and efficacy results of the add-on Parsaclisib study in patients with myelofibrosis and suboptimal response. This is the final results of a phase 2 study. Ruxolitinib has been approved for myelofibrosis, for clinical benefits. That includes splenic reduction, symptom improvement, and survival advantage. However, some…

MPN: ASH 2022 Abdulraheem Yacoub Add-on of Parsaclisib By Abdulraheem Yacoub, MD What were the results of the MPN (myeloproliferative neoplasm) Study of the add-on of Parsaclisib to Ruxolitinib therapy? At the American Society of Hematology (ASH) 2022 in New Orleans, I had the opportunity to present the final safety and efficacy results of the add-on Parsaclisib study in patients with myelofibrosis and suboptimal response. This is the final results of a phase 2 study. Ruxolitinib has been approved for myelofibrosis, for clinical benefits. That includes splenic reduction, symptom improvement, and survival advantage. However, some patients manifest a suboptimal…

PTG-300: ASH 2022 Srdan Verstovsek Verify Phase 3 Clinical Trial By Srdan Verstovsek, MD, PhD What were the results of the PTG-300 Verify phase 3 clinical trial in polycythemia vera patients? The study (design) of interest is the primary session report of the development of new antibody, and that antibody is against a mutated calreticulin. Now, what is the mutated calreticulin? In all the patients with myeloproliferative, neoplasms being ET or PV (diagnosis polycythemia vera) or myelofibrosis, there is a hyperactivity of intercellular signal. … JTA pathway, and this is because of our CE mutations in about 30% of the…

iFrame is not supported! PTG-300: ASH 2022 Srdan Verstovsek Verify Phase 3 Clinical Trial By Srdan Verstovsek, MD, PhD What were the results of the PTG-300 Verify phase 3 clinical trial in polycythemia vera patients? The study (design) of interest is the primary session report of the development of new antibody, and that antibody is against a mutated calreticulin. Now, what is the mutated calreticulin? In all the patients with myeloproliferative, neoplasms being ET or PV (diagnosis polycythemia vera) or myelofibrosis, there is a hyperactivity of intercellular signal. JTA pathway, and this is because of our CE mutations in…

PTG-300: ASH 2022 Srdan Verstovsek Verify Phase 3 Clinical Trial By Srdan Verstovsek, MD, PhD What were the results of the PTG-300 Verify phase 3 clinical trial in polycythemia vera patients? The study (design) of interest is the primary session report of the development of new antibody, and that antibody is against a mutated calreticulin. Now, what is the mutated calreticulin? In all the patients with myeloproliferative, neoplasms being ET or PV (diagnosis polycythemia vera) or myelofibrosis, there is a hyperactivity of intercellular signal. JTA pathway, and this is because of our CE mutations in about 30% of the…

For this year’s Targeted Therapies Forum, Dr. Chul Kim, Assistant Professor, Georgetown University; Hematology/ Medical Oncology; Attending Physician at MedStar Georgetown University Hospital, talks about Managing Treatment Toxicities: A Practical Approach. In this video, Dr. Chul Kim discusses possible side effects from ROS1-TKIs, including dysgeusia, and neurologic events. We thank our sponsors for this year’s support! #novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s Targeted Therapies Forum, Dr. Chul Kim, Assistant Professor, Georgetown University; Hematology/ Medical Oncology; Attending Physician at MedStar Georgetown University Hospital, talks about Managing Treatment Toxicities: A Practical Approach. In this video, Dr. Chul Kim analyzes possible side effects of ALK-TKIs, including hypercholesterolemia, pulmonary events, and cognitive effects. We thank our sponsors for this year’s support! #novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s Targeted Therapies Forum, Dr. Chul Kim, Assistant Professor, Georgetown University; Hematology/ Medical Oncology; Attending Physician at MedStar Georgetown University Hospital, talks about Managing Treatment Toxicities: A Practical Approach. In this video, Dr. Chul Kim examines two rare side effects of EGFR-TKIs: pneumonitis and cardiotoxicity We thank our sponsors for this year’s support! #hormonetherapy #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s Targeted Therapies Forum, Dr. Chul Kim, Assistant Professor, Georgetown University; Hematology/ Medical Oncology; Attending Physician at MedStar Georgetown University Hospital, talks about Managing Treatment Toxicities: A Practical Approach. In this video, Dr. Chul Kim discusses management of two possible side effects of EGFR-TKIs: stomatitis and diarrhea. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s Targeted Therapies Forum, Dr. Chul Kim, Assistant Professor, Georgetown University; Hematology/ Medical Oncology; Attending Physician at MedStar Georgetown University Hospital, talks about Managing Treatment Toxicities: A Practical Approach. In this video, Dr. Chul Kim discusses dermatologic side effects of EGFR TKIs, including pruritis, xerosis, paronychia, and acneiform rash. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s Targeted Therapies Forum, Dr. Narjust Florez, Associate Director, Cancer Care Equity Program, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School; Thoracic Oncologist, Lowe Center for Thoracic Oncology, Dana Farber Cancer Insititute, discusses the Management of Oligoprogression in Mutated Advanced NSCLC. In this video, Dr. Narjust Florez examines oligoprogression specifically in EGFR Mutant NSCLC. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s Targeted Therapies Forum, Dr. Narjust Florez, Associate Director, Cancer Care Equity Program, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School; Thoracic Oncologist, Lowe Center for Thoracic Oncology, Dana Farber Cancer Insititute, discusses the Management of Oligoprogression in Mutated Advanced NSCLC. In this video, Dr. Narjust Florez discusses how oligoprogression is treated, focusing on local therapies. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s Targeted Therapies Forum, Dr. Narjust Florez, Associate Director, Cancer Care Equity Program, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School; Thoracic Oncologist, Lowe Center for Thoracic Oncology, Dana Farber Cancer Insititute, discusses the Management of Oligoprogression in Mutated Advanced NSCLC.In this video, Dr. Narjust Florez discusses how to identify oligoprogression of disease.For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s Targeted Therapies Forum, Dr. Narjust Florez, Associate Director, Cancer Care Equity Program, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School; Thoracic Oncologist, Lowe Center for Thoracic Oncology, Dana Farber Cancer Insititute, discusses the Management of Oligoprogression in Mutated Advanced NSCLC. In this video, Dr. Narjust Florez explains what defines oligoprogression of disease. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Pembro: ASH 2022 Mwanasha Merrill Addition After Auto-SCT T-Cell NHL By Mwanasha Merrill, MD How can Pembro (MK-3475) help patients with with -cell non-hodgkin lymphoma? I’m excited about this phase 2 Pembro (MK-3475) study, Pembrolizumab after autologous stem cell transplant in patients with T-cell lymphoma. As most rare for T-cell lymphomas have a poor prognosis and it’s really hard for developing new therapies given the heterogeneous nature of this disease and currently high dose chemotherapy and consolidation with an autologous stem-cell transplant is recommended in first remission. And however, at the moment we also do not have any options for…

iFrame is not supported! Pembro: ASH 2022 Mwanasha Merrill Addition After Auto-SCT T-Cell NHL By Mwanasha Merrill, MD How can Pembro (MK-3475) help patients with with -cell non-hodgkin lymphoma? I’m excited about this phase 2 Pembro (MK-3475) study, Pembrolizumab after autologous stem cell transplant in patients with T-cell lymphoma. As most rare for T-cell lymphomas have a poor prognosis and it’s really hard for developing new therapies given the heterogeneous nature of this disease and currently high dose chemotherapy and consolidation with an autologous stem-cell transplant is recommended in first remission. And however, at the moment we also do not…

Pembro: ASH 2022 Mwanasha Merrill Addition After Auto-SCT T-Cell NHL By Mwanasha Merrill, MD How can Pembro (MK-3475) help patients with with -cell non-hodgkin lymphoma? I’m excited about this phase 2 Pembro (MK-3475) study, Pembrolizumab after autologous stem cell transplant in patients with T-cell lymphoma. As most rare for T-cell lymphomas have a poor prognosis and it’s really hard for developing new therapies given the heterogeneous nature of this disease and currently high dose chemotherapy and consolidation with an autologous stem-cell transplant is recommended in first remission. And however, at the moment we also do not have any options for…

MRD: ASH 2022 Gayathri Ravi Induction Quadruplet Therapy in NDMM By Gayathri Ravi, MD What can induction quadruplet therapy do for patients with Newly Diagnosed Multiple Myeloma (NDMM) and does that include next-generation sequencing? So we adopted a institutional strategy to start do quadruplet induction therapy with a 4 drug-based induction for multiple myeloma from the March of 2020. And since UAB is the only transplant center in the state of Alabama, we have entire state of population who are transplant eligible and are nearly diagnosed with multiple myeloma referred to UAB for transplant. So we have an established communication…

iFrame is not supported! MRD: ASH 2022 Gayathri Ravi Induction Quadruplet Therapy in NDMM By Gayathri Ravi, MD What can induction quadruplet therapy do for patients with Newly Diagnosed Multiple Myeloma (NDMM) and does that include next-generation sequencing? So we adopted a institutional strategy to start do quadruplet induction therapy with a 4 drug-based induction for multiple myeloma from the March of 2020. And since UAB is the only transplant center in the state of Alabama, we have entire state of population who are transplant eligible and are nearly diagnosed with multiple myeloma referred to UAB for transplant. So we…

MRD: ASH 2022 Gayathri Ravi Induction Quadruplet Therapy in NDMM By Gayathri Ravi, MD What can induction quadruplet therapy do for patients with Newly Diagnosed Multiple Myeloma (NDMM) and does that include next-generation sequencing? So we adopted a institutional strategy to start do quadruplet induction therapy with a 4 drug-based induction for multiple myeloma from the March of 2020. And since UAB is the only transplant center in the state of Alabama, we have entire state of population who are transplant eligible and are nearly diagnosed with multiple myeloma referred to UAB for transplant. So we have an established communication…

PI3Kα: SABCS 2022 Axel Hoos STX-478 Xenograft Models Breast Cancer How can a PI3Kα inhibitor help patients suffering with breast cancer? The company that I represent is Scorpion Therapeutics, our focus is on elevating the entire game for precision oncology, so using targeted molecules that go after mutations and cancer and optimize outcomes for patients. So we call that Precision Oncology 2.0, now what we’re presenting here at SABCS is basically data on our lead compound, a PI3Kα inhibitor that is mutation selective. We call it STX-478, that has shown very high level, a selectivity against specific (oncogenic) mutations…

iFrame is not supported! PI3Kα: SABCS 2022 Axel Hoos STX-478 Xenograft Models Breast Cancer How can a PI3Kα inhibitor help patients suffering with breast cancer? The company that I represent is Scorpion Therapeutics, our focus is on elevating the entire game for precision oncology, so using targeted molecules that go after mutations and cancer and optimize outcomes for patients. So we call that Precision Oncology 2.0, now what we’re presenting here at SABCS is basically data on our lead compound, a PI3Kα inhibitor that is mutation selective. We call it STX-478, that has shown very high level, a selectivity against…

PI3Kα: SABCS 2022 Axel Hoos STX-478 Xenograft Models Breast Cancer How can a PI3Kα inhibitor help patients suffering with breast cancer? The company that I represent is Scorpion Therapeutics, our focus is on elevating the entire game for precision oncology, so using targeted molecules that go after mutations and cancer and optimize outcomes for patients. So we call that Precision Oncology 2.0, now what we’re presenting here at SABCS is basically data on our lead compound, a PI3Kα inhibitor that is mutation selective. We call it STX-478, that has shown very high level, a selectivity against specific (oncogenic) mutations…

Sacituzumab Govitecan: SABCS 2022 Hope Rugo EAIRs of AEs TROPiCS-02 What does Sacituzumab Govitecan trial results show for patients with HR+/HER2- metastatic breast cancer (MBC)? Sacituzumab Govitecan is a first in class Trop-2-directed antibody-drug conjugates linked to a Topoisomerase 1 inhibitor. The active metabolite of Irinotecan SN-38 Sacituzumab is already FDA approved for the treatment of metastatic Triple-negative breast cancer (TNBC) in patients who’ve received at least one line of prior chemotherapy based on data from the ASCENT trial. Where it showed improvement in progression-free and overall survival compared to chemotherapy of physician choice. In an initial phase one Umbrella…

iFrame is not supported! Sacituzumab Govitecan: SABCS 2022 Hope Rugo EAIRs of AEs TROPiCS-02 What does Sacituzumab Govitecan trial results show for patients with HR+/HER2- metastatic breast cancer (MBC)? Sacituzumab Govitecan is a first in class Trop-2-directed antibody-drug conjugates linked to a Topoisomerase 1 inhibitor. The active metabolite of Irinotecan SN-38 Sacituzumab is already FDA approved for the treatment of metastatic Triple-negative breast cancer (TNBC) in patients who’ve received at least one line of prior chemotherapy based on data from the ASCENT trial. Where it showed improvement in progression-free and overall survival compared to chemotherapy of physician choice. In an…

Sacituzumab Govitecan: SABCS 2022 Hope Rugo EAIRs of AEs TROPiCS-02 What does Sacituzumab Govitecan trial results show for patients with HR+/HER2- metastatic breast cancer (MBC)? Sacituzumab Govitecan is a first in class Trop-2-directed antibody-drug conjugates linked to a Topoisomerase 1 inhibitor. The active metabolite of Irinotecan SN-38 Sacituzumab is already FDA approved for the treatment of metastatic Triple-negative breast cancer (TNBC) in patients who’ve received at least one line of prior chemotherapy based on data from the ASCENT trial. Where it showed improvement in progression-free and overall survival compared to chemotherapy of physician choice. In an initial phase one Umbrella…

ARV-471: SABCS 2022 Ron Peck Phase 2 Expansion VERITAC Trial What can this PROTAC estrogen receptor degrader do for patients with metastatic breast cancer? ARV-471 is a PROTAC targeted protein degrader, so unlike surges, what it does is it tar targets the estrogen receptor and it hijacks. The cell zone machinery for degrading proteins the ubiquitous proteasome system. So this is a very potent ER degrader and the trial that was presented this morning was the VERITAC phase 2 study. And this is a study that was evaluating 2 different doses that were determined based on our phase one.…

iFrame is not supported! ARV-471: SABCS 2022 Ron Peck Phase 2 Expansion VERITAC Trial What can this PROTAC estrogen receptor degrader do for patients with metastatic breast cancer? ARV-471 is a PROTAC targeted protein degrader, so unlike surges, what it does is it tar targets the estrogen receptor and it hijacks. The cell zone machinery for degrading proteins the ubiquitous proteasome system. So this is a very potent ER degrader and the trial that was presented this morning was the VERITAC phase 2 study. And this is a study that was evaluating 2 different doses that were determined based…

ARV-471: SABCS 2022 Ron Peck Phase 2 Expansion VERITAC Trial What can this PROTAC estrogen receptor degrader do for patients with metastatic breast cancer? ARV-471 is a PROTAC targeted protein degrader, so unlike surges, what it does is it tar targets the estrogen receptor and it hijacks. The cell zone machinery for degrading proteins the ubiquitous proteasome system. So this is a very potent ER degrader and the trial that was presented this morning was the VERITAC phase 2 study. And this is a study that was evaluating 2 different doses that were determined based on our phase one.…

For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University of Alabama Birmingham; Dr. Rana McKay, Medical Oncologist, Associate Professor of Medicine, UC San Diego; and Dr. Medhavi Gupta, Hematologist-Oncologist, Roswell Park Comprehensive Cancer Center, Assistant Professor of Medicine, Brown University, present the importance about Testing and Early Diagnosis in Cancer. In this video, Dr. Medhavi Gupta reiterates the importance of breast cancer screening in detection and treatment. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University of Alabama Birmingham; Dr. Rana McKay, Medical Oncologist, Associate Professor of Medicine, UC San Diego; and Dr. Medhavi Gupta, Hematologist-Oncologist, Roswell Park Comprehensive Cancer Center, Assistant Professor of Medicine, Brown University, present the importance about Testing and Early Diagnosis for Lung Cancer. In this video, Dr. Medhavi Gupta examines how treatment can look for patients diagnosed with breast cancer. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University of Alabama Birmingham; Dr. Rana McKay, Medical Oncologist, Associate Professor of Medicine, UC San Diego; and Dr. Medhavi Gupta, Hematologist-Oncologist, Roswell Park Comprehensive Cancer Center, Assistant Professor of Medicine, Brown University, present the importance about Testing and Early Diagnosis for Lung Cancer. In this video, Dr. Medhavi Gupta discusses symptoms that may be seen in patients with breast cancer. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University of Alabama Birmingham; Dr. Rana McKay, Medical Oncologist, Associate Professor of Medicine, UC San Diego; and Dr. Medhavi Gupta, Hematologist-Oncologist, Roswell Park Comprehensive Cancer Center, Assistant Professor of Medicine, Brown University, present the importance about Testing and Early Diagnosis. In this video, Dr. Medhavi Gupta examines the steps a patient could go through after an abnormality is found on a breast cancer screening. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University of Alabama Birmingham; Dr. Rana McKay, Medical Oncologist, Associate Professor of Medicine, UC San Diego; and Dr. Medhavi Gupta, Hematologist-Oncologist, Roswell Park Comprehensive Cancer Center, Assistant Professor of Medicine, Brown University, present the importance about Testing and Early Diagnosis for Lung Cancer. In this video, Dr. Medhavi Gupta discusses mammograms, ultrasounds, and MRIs for breast cancer screening. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University of Alabama Birmingham; Dr. Rana McKay, Medical Oncologist, Associate Professor of Medicine, UC San Diego; and Dr. Medhavi Gupta, Hematologist-Oncologist, Roswell Park Comprehensive Cancer Center, Assistant Professor of Medicine, Brown University, present the importance about Testing and Early Diagnosis for Lung Cancer. In this video, Dr. Medhavi Gupta discusses how common breast cancer is, and why it is crucial to get screened. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University of Alabama Birmingham; Dr. Rana McKay, Medical Oncologist, Associate Professor of Medicine, UC San Diego; and Dr. Medhavi Gupta, Hematologist-Oncologist, Roswell Park Comprehensive Cancer Center, Assistant Professor of Medicine, Brown University, present the importance about Testing and Early Diagnosis. In this video, Dr. Rana McKay discusses why it’s crucial to get a prostate cancer screening. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University of Alabama Birmingham; Dr. Rana McKay, Medical Oncologist, Associate Professor of Medicine, UC San Diego; and Dr. Medhavi Gupta, Hematologist-Oncologist, Roswell Park Comprehensive Cancer Center, Assistant Professor of Medicine, Brown University, present the importance about Testing and Early Diagnosis for Lung Cancer. In this video, Dr. Devika Das examines the importance of patient centered care, including safety throughout the process, and equitable care for all. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University of Alabama Birmingham; Dr. Rana McKay, Medical Oncologist, Associate Professor of Medicine, UC San Diego; and Dr. Medhavi Gupta, Hematologist-Oncologist, Roswell Park Comprehensive Cancer Center, Assistant Professor of Medicine, Brown University, present the importance about Testing and Early Diagnosis for Lung Cancer. In this video, Dr. Devika Das discusses the importance of staging of cancer, and of testing for mutations. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University of Alabama Birmingham; Dr. Rana McKay, Medical Oncologist, Associate Professor of Medicine, UC San Diego; and Dr. Medhavi Gupta, Hematologist-Oncologist, Roswell Park Comprehensive Cancer Center, Assistant Professor of Medicine, Brown University, present the importance about Testing and Early Diagnosis for Lung Cancer. In this video, Dr. Devika Das discusses the importance of staging of cancer, and of testing for mutations. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University of Alabama Birmingham; Dr. Rana McKay, Medical Oncologist, Associate Professor of Medicine, UC San Diego; and Dr. Medhavi Gupta, Hematologist-Oncologist, Roswell Park Comprehensive Cancer Center, Assistant Professor of Medicine, Brown University, present the importance about Testing and Early Diagnosis for Lung Cancer. In this video, Dr. Devika Das examines the first domain of quality cancer care: finding the cancer early. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University of Alabama Birmingham; Dr. Rana McKay, Medical Oncologist, Associate Professor of Medicine, UC San Diego; and Dr. Medhavi Gupta, Hematologist-Oncologist, Roswell Park Comprehensive Cancer Center, Assistant Professor of Medicine, Brown University, present the importance about Testing and Early Diagnosis for Lung Cancer. In this video, Dr. Devika Das talks about goals for lung cancer advocacy, including broader testing. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University of Alabama Birmingham; Dr. Rana McKay, Medical Oncologist, Associate Professor of Medicine, UC San Diego; and Dr. Medhavi Gupta, Hematologist-Oncologist, Roswell Park Comprehensive Cancer Center, Assistant Professor of Medicine, Brown University, present the importance about Testing and Early Diagnosis for Lung Cancer. In this video, Dr. Devika Das discusses comprehensive care in lung cancer, and who is involved from screening to treatment. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University of Alabama Birmingham; Dr. Rana McKay, Medical Oncologist, Associate Professor of Medicine, UC San Diego; and Dr. Medhavi Gupta, Hematologist-Oncologist, Roswell Park Comprehensive Cancer Center, Assistant Professor of Medicine, Brown University, present the importance about Testing and Early Diagnosis for Lung Cancer. In this video, Dr. Devika Das explains the process of getting a lung cancer screening. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University of Alabama Birmingham; Dr. Rana McKay, Medical Oncologist, Associate Professor of Medicine, UC San Diego; and Dr. Medhavi Gupta, Hematologist-Oncologist, Roswell Park Comprehensive Cancer Center, Assistant Professor of Medicine, Brown University, present the importance about Testing and Early Diagnosis for Lung Cancer. In this video, Dr. Devika Das discusses which patients should receive lung cancer screening. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University of Alabama Birmingham; Dr. Rana McKay, Medical Oncologist, Associate Professor of Medicine, UC San Diego; and Dr. Medhavi Gupta, Hematologist-Oncologist, Roswell Park Comprehensive Cancer Center, Assistant Professor of Medicine, Brown University, present the importance about Testing and Early Diagnosis for Lung Cancer. In this video, Dr. Devika Das gives a brief overview of the importance of lung cancer screening during a pandemic. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s Targeted Therapies Forum, Dr. Fred R Hirsch, Executive Director, Center for Thoracic Oncology at Mount Sinai; Joe Lowe and Lewis Price Professor of Medicine, Icahn School of Medicine and Associate Director, Biomarker Discovery for TCI, presents Genetic Testing in Lung Cancer. In this video, Dr. Fred Hirsch discusses the importance of biomarker testing, as well as disparities that exist in the field. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s Targeted Therapies Forum, Dr. Fred R Hirsch, Executive Director, Center for Thoracic Oncology at Mount Sinai; Joe Lowe and Lewis Price Professor of Medicine, Icahn School of Medicine and Associate Director, Biomarker Discovery for TCI, presents Genetic Testing in Lung Cancer. In this video, Dr. Fred Hirsch examines liquid biopsies and their current and future role in diagnosis. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s Targeted Therapies Forum, Dr. Fred R Hirsch, Executive Director, Center for Thoracic Oncology at Mount Sinai; Joe Lowe and Lewis Price Professor of Medicine, Icahn School of Medicine and Associate Director, Biomarker Discovery for TCI, presents Genetic Testing in Lung Cancer. In this video, Dr. Fred Hirsch discusses the ALK, RET, and MET mutations. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this series, Dr. Kwon discusses the decision-making process with Fred, who has recurrent prostate cancer and is making an important decision about hormone therapy. Fred candidly discusses his decision-making process and what he has learned through his cancer journey. In this video, Dr. Kwon and Fred discuss resources for patients with cancer. For a full list of resources, please visit the cancerGRACE site at https://cancergrace.org/video-collection/patient-education-ambassador-program, or see these links, below: Making Cancer Decisions – https://www.cancer.net/navigating-cancer-care/how-cancer-treated/making-decisions-about-cancer-treatment UCSF’s Advanced Prostate Cancer Patient Guide – https://urology.ucsf.edu/sites/urology.ucsf.edu/files/uploaded-files/attachments/sduro0215_advanced_prostate_cancer_and_its_treatment-a_patient_guide.pdf Non-profit organizations – Prostate Cancer Foundation – https://www.pcf.org/ – American Society of Clinical Oncology – https://www.cancer.net/…

For this series, Dr. Kwon discusses the decision-making process with Fred, who has recurrent prostate cancer and is making an important decision about hormone therapy. Fred candidly discusses his decision-making process and what he has learned through his cancer journey. In this video, Dr. Kwon and Fred discuss personal preferences in the decision-making process. For resources and tools, please see the links available in the description of the last video in this series, or visit the cancerGRACE site at https://cancergrace.org/video-collection/patient-education-ambassador-program For more, please visit https://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. #prostatecancer #cancer #cancerresources #exelixis #lilly #genentech #hormonetherapy

For this series, Dr. Kwon discusses the decision-making process with Fred, who has recurrent prostate cancer and is making an important decision about hormone therapy. Fred candidly discusses his decision-making process and what he has learned through his cancer journey. In this video, Dr. Kwon and Fred discuss the option of waiting to start hormone treatment. For resources and tools, please see the links available in the description of the last video in this series, or visit the cancerGRACE site at https://cancergrace.org/video-collection/patient-education-ambassador-program For more, please visit https://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. #prostatecancer #cancer #cancerresources #exelixis #lilly #genentech #hormonetherapy

For this year’s Targeted Therapies Forum, Dr. Fred R Hirsch, Executive Director, Center for Thoracic Oncology at Mount Sinai; Joe Lowe and Lewis Price Professor of Medicine, Icahn School of Medicine and Associate Director, Biomarker Discovery for TCI, presents Genetic Testing in Lung Cancer. In this video, Dr. Fred Hirsch looks at KRAS mutations in advanced disease. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s Targeted Therapies Forum, Dr. Fred R Hirsch, Executive Director, Center for Thoracic Oncology at Mount Sinai; Joe Lowe and Lewis Price Professor of Medicine, Icahn School of Medicine and Associate Director, Biomarker Discovery for TCI, presents Genetic Testing in Lung Cancer. In this video, Dr. Fred Hirsch talks briefly about Exon 20, and the importance of the Destiny Trial for patients with HER2. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s Targeted Therapies Forum, Dr. Fred R Hirsch, Executive Director, Center for Thoracic Oncology at Mount Sinai; Joe Lowe and Lewis Price Professor of Medicine, Icahn School of Medicine and Associate Director, Biomarker Discovery for TCI, presents Genetic Testing in Lung Cancer. In this video, Dr. Fred Hirsch discusses the ADAURA Trial, which tested Osimertinib for early stage EGFR+ NSCLC. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s Targeted Therapies Forum, Dr. Fred R Hirsch, Executive Director, Center for Thoracic Oncology at Mount Sinai; Joe Lowe and Lewis Price Professor of Medicine, Icahn School of Medicine and Associate Director, Biomarker Discovery for TCI, presents Genetic Testing in Lung Cancer. In this video, Dr. Fred Hirsch looks at the drug combination of Amivantamab and Lazertinib in EGFR MET+ disease. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s Targeted Therapies Forum, Dr. Fred R Hirsch, Executive Director, Center for Thoracic Oncology at Mount Sinai; Joe Lowe and Lewis Price Professor of Medicine, Icahn School of Medicine and Associate Director, Biomarker Discovery for TCI, presents Genetic Testing in Lung Cancer. In this video, Dr. Fred Hirsch discusses options when a patient with EGFR+ NSCLC develops acquired resistance to Osimertinib. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this series, Dr. Kwon discusses the decision-making process with Fred, who has recurrent prostate cancer and is making an important decision about hormone therapy. Fred candidly discusses his decision-making process and what he has learned through his cancer journey. In this video, Dr. Kwon and Fred discuss his first option: starting hormone treatment immediately and its risks/benefits. For resources and tools, please see the links available in the description of the last video in this series, or visit the cancerGRACE site at https://cancergrace.org/video-collection/patient-education-ambassador-program For more, please visit https://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. #prostatecancer #cancer #cancerresources #exelixis #lilly…

For this series, Dr. Kwon discusses the decision-making process with Fred, who has recurrent prostate cancer and is making an important decision about hormone therapy. Fred candidly discusses his decision-making process and what he has learned through his cancer journey. In this video, Dr. Kwon and Fred discuss his treatment options for prostate cancer: starting androgen deprivation therapy immediately versus later. For resources and tools, please see the links available in the description of the last video in this series, or visit the cancerGRACE site at https://cancergrace.org/video-collection/patient-education-ambassador-program #prostatecancer #cancer #cancerresources #exelixis #lilly #genentech #hormonetherapy For more, please visit https://cancerGRACE.org/. To…

For this year’s Targeted Therapies Forum, Dr. Fred R Hirsch, Executive Director, Center for Thoracic Oncology at Mount Sinai; Joe Lowe and Lewis Price Professor of Medicine, Icahn School of Medicine and Associate Director, Biomarker Discovery for TCI, presents Genetic Testing in Lung Cancer. In this video, Dr. Fred Hirsch examines treatment options for EGFR+ NSCLC. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s Targeted Therapies Forum, Dr. Fred R Hirsch, Executive Director, Center for Thoracic Oncology at Mount Sinai; Joe Lowe and Lewis Price Professor of Medicine, Icahn School of Medicine and Associate Director, Biomarker Discovery for TCI, presents Genetic Testing in Lung Cancer. In this video, Dr. Fred Hirsch discusses the advantages of Next Generation Sequencing. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s Targeted Therapies Forum, Dr. Fred R Hirsch, Executive Director, Center for Thoracic Oncology at Mount Sinai; Joe Lowe and Lewis Price Professor of Medicine, Icahn School of Medicine and Associate Director, Biomarker Discovery for TCI, presents Genetic Testing in Lung Cancer. In this video, Dr. Fred Hirsch examines the concept of targeted driver mutations in NSCLC treatment. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s Targeted Therapies Forum, Dr. Fred R Hirsch, Executive Director, Center for Thoracic Oncology at Mount Sinai; Joe Lowe and Lewis Price Professor of Medicine, Icahn School of Medicine and Associate Director, Biomarker Discovery for TCI, presents Genetic Testing in Lung Cancer. In this video, Dr. Fred Hirsch talks about the changes in the first-line treatment of metastatic NSCLC over the past 2 decades. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

In this video series Dr. Kathryn Gold, Medical Oncologist, specialized in lung, head and neck, Professor, Department of Medicine, UC San Diego, and Dr. Siddharth Sheth, Medical oncologist, Assistant Professor of Medicine, Division of Medical Oncology, UNC Chapel Hill, discuss the newest updates in head and neck cancer, presented at ASCO 2022. Drs. Sheth and Gold examine a drug that treats oral mucositis. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

In this video series Dr. Kathryn Gold, Medical Oncologist, specialized in lung, head and neck, Professor, Department of Medicine, UC San Diego, and Dr. Siddharth Sheth, Medical oncologist, Assistant Professor of Medicine, Division of Medical Oncology, UNC Chapel Hill, discuss the newest updates in head and neck cancer, presented at ASCO 2022. Drs. Sheth and Gold look at the importance of CT and HPV DNA in treatment of head and neck cancer. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

In this video series Dr. Kathryn Gold, Medical Oncologist, specialized in lung, head and neck, Professor, Department of Medicine, UC San Diego, and Dr. Siddharth Sheth, Medical oncologist, Assistant Professor of Medicine, Division of Medical Oncology, UNC Chapel Hill, discuss the newest updates in head and neck cancer, presented at ASCO 2022. Drs. Sheth and Gold examine possible treatment combinations for head and neck cancer. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

In this video series Dr. Kathryn Gold, Medical Oncologist, specialized in lung, head and neck, Professor, Department of Medicine, UC San Diego, and Dr. Siddharth Sheth, Medical oncologist, Assistant Professor of Medicine, Division of Medical Oncology, UNC Chapel Hill, discuss the newest updates in head and neck cancer, presented at ASCO 2022. Drs. Sheth and Gold discuss how to treat patients with recurrent or metastatic head and neck cancer. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

In this video series Dr. Kathryn Gold, Medical Oncologist, specialized in lung, head and neck, Professor, Department of Medicine, UC San Diego, and Dr. Siddharth Sheth, Medical oncologist, Assistant Professor of Medicine, Division of Medical Oncology, UNC Chapel Hill, discuss the newest updates in head and neck cancer, presented at ASCO 2022. Drs. Sheth and Gold talk about the effectiveness of immunotherapy in head and neck cancer treatment. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

In this video series Dr. Kathryn Gold, Medical Oncologist, specialized in lung, head and neck, Professor, Department of Medicine, UC San Diego, and Dr. Siddharth Sheth, Medical oncologist, Assistant Professor of Medicine, Division of Medical Oncology, UNC Chapel Hill, discuss the newest updates in head and neck cancer, presented at ASCO 2022. In this video, Drs. Sheth and Gold examine the benefit of weekly cisplatin usage for patients with head and neck cancer. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

In this video series Dr. Kathryn Gold, Medical Oncologist specializing in lung, head and neck cancers, Professor with the Department of Medicine, UC San Diego, and Dr. Siddharth Sheth, Medical oncologist, Assistant Professor of Medicine, Division of Medical Oncology at UNC Chapel Hill, discuss the newest updates in head and neck cancer, presented at ASCO 2022. Drs. Sheth and Gold discuss emerging information on deintensification for nasopharyngeal cancer. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

El Dr. Eric Singh, uno de los participantes en el Programa de Embajadores de Educación para Pacientes GRACE del año pasado, produjo este excelente video para nuestra comunidad de habla hispana, sobre visitas de oncología médica. Este video proporciona una guía del paciente para la visita inicial de oncología médica. Para descargar las notas útiles del Dr. Singh, visite https://cancergrace.org/video-collection/patient-education-ambassador-program, https://cancergrace.org/sites/default/files/2022-08/GUIÏA%20DEL%20PACIENTE%20PARA%20LA%20VISITA%20INICIAL%20DE%20ONCOLOGIÏA%20MEÏDICA_Spanish.pdf Para obtener más información, visite http://cancerGRACE.org/. Para unirse a la conversación, visite https://cancergrace.org/forum.

Dr. Eric Singh, one of the participants in this past year’s GRACE Patient Education Ambassador Program, produced this great video for our English-speaking community, on medical oncology visits. This video provides a patient’s guide to the initial medical oncology visit. To download Dr. Singh’s helpful notes, please visit https://cancergrace.org/video-collection/patient-education-ambassador-program and https://cancergrace.org/sites/default/files/2022-08/Patient%20Guide%20to%20Initial%20Medical%20Oncology%20Visit_English.pdf. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s post-ASCO Lung Cancer roundtable review, Drs. H.Jack West, Oncologist with City of Hope Comprehensive Cancer Center and Founder and President of GRACE, Jarushka Naidoo, Medical Oncologist and Assistant Professor with Sidney Kimmel Cancer Center at Johns Hopkins, and Gilberto Lopes, Chief Medical Oncologist with Sylvester Comprehensive Cancer Center, discuss the newest updates in lung cancer, presented at ASCO 2022. In this video Drs. West, Naidoo, and Lopes look at the Checkmate 816 study, which examined chemo combined with Opdivo in patients with 1B to 3A disease. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s post-ASCO Lung Cancer roundtable review, Drs. H.Jack West, Oncologist with City of Hope Comprehensive Cancer Center and Founder and President of GRACE, Jarushka Naidoo, Medical Oncologist and Assistant Professor with Sidney Kimmel Cancer Center at Johns Hopkins, and Gilberto Lopes, Chief Medical Oncologist with Sylvester Comprehensive Cancer Center, discuss the newest updates in lung cancer, presented at ASCO 2022. In this video Drs. West, Naidoo, and Lopes discuss the results of the Skyscraper Trial, which looked at small cell lung cancer. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s post-ASCO Lung Cancer roundtable review, Drs. H.Jack West, Oncologist with City of Hope Comprehensive Cancer Center and Founder and President of GRACE, Jarushka Naidoo, Medical Oncologist and Assistant Professor with Sidney Kimmel Cancer Center at Johns Hopkins, and Gilberto Lopes, Chief Medical Oncologist with Sylvester Comprehensive Cancer Center, discuss the newest updates in lung cancer, presented at ASCO 2022. In this video Drs. West, Naidoo, and Lopes examine the use of Patritumab Deruxtecan in patients without particular mutations. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s post-ASCO Lung Cancer roundtable review, Drs. H.Jack West, Oncologist with City of Hope Comprehensive Cancer Center and Founder and President of GRACE, Jarushka Naidoo, Medical Oncologist and Assistant Professor with Sidney Kimmel Cancer Center at Johns Hopkins, and Gilberto Lopes, Chief Medical Oncologist with Sylvester Comprehensive Cancer Center, discuss the newest updates in lung cancer, presented at ASCO 2022. In this video Drs. West, Naidoo, and Lopes discuss the use of Durvalumab in patients with EGFRm+ NSCLC. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s post-ASCO Lung Cancer roundtable review, Drs. H.Jack West, Oncologist with City of Hope Comprehensive Cancer Center and Founder and President of GRACE, Jarushka Naidoo, Medical Oncologist and Assistant Professor with Sidney Kimmel Cancer Center at Johns Hopkins, and Gilberto Lopes, Chief Medical Oncologist with Sylvester Comprehensive Cancer Center, discuss the newest updates in lung cancer, presented at ASCO 2022. In this video Drs. West, Naidoo, and Lopes discuss the use of Rybrevant/Lazertinib in patients with EGFRm+ acquired resistance. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s post-ASCO Lung Cancer roundtable review, Drs. H.Jack West, Oncologist with City of Hope Comprehensive Cancer Center and Founder and President of GRACE, Jarushka Naidoo, Medical Oncologist and Assistant Professor with Sidney Kimmel Cancer Center at Johns Hopkins, and Gilberto Lopes, Chief Medical Oncologist with Sylvester Comprehensive Cancer Center, discuss the newest updates in lung cancer, presented at ASCO 2022. In this video Drs. West, Naidoo, and Lopes look at data that suggests patients with previously treated advanced NSCLC may respond to Keytruda combined with Anti-VEGF Treatment. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s post-ASCO Lung Cancer roundtable review, Drs. H.Jack West, Oncologist with City of Hope Comprehensive Cancer Center and Founder and President of GRACE, Jarushka Naidoo, Medical Oncologist and Assistant Professor with Sidney Kimmel Cancer Center at Johns Hopkins, and Gilberto Lopes, Chief Medical Oncologist with Sylvester Comprehensive Cancer Center, discuss the newest updates in lung cancer, presented at ASCO 2022. In this video Drs. West, Naidoo, and Lopes discuss a study showing positive results for Adagrasib in previously treated disease. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s post-ASCO Lung Cancer roundtable review, Drs. H.Jack West, Oncologist with City of Hope Comprehensive Cancer Center and Founder and President of GRACE, Jarushka Naidoo, Medical Oncologist and Assistant Professor with Sidney Kimmel Cancer Center at Johns Hopkins, and Gilberto Lopes, Chief Medical Oncologist with Sylvester Comprehensive Cancer Center, discuss the newest updates in lung cancer, presented at ASCO 2022. In this video Drs. West, Naidoo, and Lopes examine an FDA analysis that states patients with a KRAS Mutation should opt for chemo and immunotherapy. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s post-ASCO Lung Cancer roundtable review, Drs. H.Jack West, Oncologist with City of Hope Comprehensive Cancer Center and Founder and President of GRACE, Jarushka Naidoo, Medical Oncologist and Assistant Professor with Sidney Kimmel Cancer Center at Johns Hopkins, and Gilberto Lopes, Chief Medical Oncologist with Sylvester Comprehensive Cancer Center, discuss the newest updates in lung cancer, presented at ASCO 2022. In this video, Drs. West, Naidoo, and Lopes discuss if patients with high PD-L1 should have immunotherapy alone, or combine with chemotherapy. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s post-ASCO Lung Cancer roundtable review, Drs. H.Jack West, Oncologist with City of Hope Comprehensive Cancer Center and Founder and President of GRACE, Jarushka Naidoo, Medical Oncologist and Assistant Professor with Sidney Kimmel Cancer Center at Johns Hopkins, and Gilberto Lopes, Chief Medical Oncologist with Sylvester Comprehensive Cancer Center, discuss the newest updates in lung cancer, presented at ASCO 2022. In this video, Drs. West, Naidoo, and Lopes discuss a study that showed overall survival increased with thorough molecular testing. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For our Mandarin-speaking community, GRACE is happy to offer updates to our Lung Cancer Video Library translated and voiced by Oliver Zheng. In this video translation, Dr. Melina Marmarelis explains how mesothelioma is diagnosed and staged. Melina Marmarelis 博士解释了间皮瘤是如何诊断和分期的。 For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For our Mandarin-speaking community, GRACE is happy to offer updates to our Lung Cancer Video Library translated and voiced by Oliver Zheng. In this video translation, Dr. Melina Marmarelis discusses the ways mesothelioma may be treated in the future. Melina Marmarelis 博士讨论了未来治疗间皮瘤的方法。 For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For our Mandarin-speaking community, GRACE is happy to offer updates to our Lung Cancer Video Library translated and voiced by Oliver Zheng. In this video translation, Dr, Chul Kim discusses Amivantamab and Mobocertinib, and their role as treatments for EGFR Exon-20 Insertion Mutations Chul Kim 博士讨论了 Amivantamab 和 Mobocertinib，以及它们作为 EGFR 外显子 20 插入突变治疗的作用 For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For our Mandarin-speaking community, GRACE is happy to offer updates to our Lung Cancer Video Library translated and voiced by Oliver Zheng. In this video translation, Dr. Ibiayi Dagogo-Jack explains the concept of “skipping” in Exon-14 NSCLC. Ibiayi Dagogo-Jack 博士解释了 Exon-14 非小细胞肺癌中”跳过”的概念。 For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For our Mandarin-speaking community, Oliver Zheng offers translated updates to our Lung Cancer Video Library. In this video translation, Dr. Christina Baik looks toward the future of treatments for patients with EGFR Exon-20. Christina Baik 博士展望 EGFR Exon-20 患者治疗的未来 For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

El Dr. Jared Weiss se une a nosotros para analizar la importancia de las pruebas y el diagnóstico temprano en la atención del cáncer, con énfasis en los cánceres de cabeza y cuello. En este video, el Dr. Jared Weiss analiza las formas de reducir el riesgo de cáncer de cabeza y cuello, con énfasis en la vacuna contra el VPH. Para obtener más información, visite http://cancerGRACE.org/. Para unirse a la conversación, visite https://cancergrace.org/forum. Gracias a nuestros patrocinadores. #Exelixis y #Merck

El Dr. Jared Weiss se une a nosotros para analizar la importancia de las pruebas y el diagnóstico temprano en la atención del cáncer, con énfasis en los cánceres de cabeza y cuello. En este video, el Dr. Jared Weiss analiza los beneficios de las pruebas regulares de detección de cáncer de cabeza y cuello. Para obtener más información, visite http://cancerGRACE.org/. Para unirse a la conversación, visite https://cancergrace.org/forum. Gracias a nuestros patrocinadores. #Exelixis y #Merck

El Dr. Jared Weiss se une a nosotros para analizar la importancia de las pruebas y el diagnóstico temprano en la atención del cáncer, con énfasis en los cánceres de cabeza y cuello. En este video, el Dr. Jared Weiss analiza los factores de riesgo de los cánceres de cabeza y cuello. Para obtener más información, visite http://cancerGRACE.org/. Para unirse a la conversación, visite https://cancergrace.org/forum. Gracias a nuestros patrocinadores. #Exelixis y #Merck

Dr. Jared Weiss joins us to discuss the importance of testing and early diagnosis in cancer care, with a concentration in head and neck cancers. In this video, Dr. Jared Weiss discusses ways to lower your risk of head and neck cancer, with emphasis on the HPV Vaccine. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. Thank you to our sponsors! #Exelixis and #Merck

Dr. Jared Weiss joins us to discuss the importance of testing and early diagnosis in cancer care, with a concentration in head and neck cancers. In this video, Dr. Jared Weiss discusses the benefits of regular screening for head and neck cancers. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. Thank you to our sponsors! #Exelixis and #Merck

Dr. Jared Weiss joins us to discuss the importance of testing and early diagnosis in cancer care, with a concentration in head and neck cancers. In this video, Dr. Jared Weiss discusses the risk factors for head and neck cancers. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. Thank you to our sponsors! #Exelixis and #Merck

July 30, 2022 – full ONDEMAND video For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s update to the Case-Based Panel Discussions program, we are pleased to work with Drs. Ana Velazquez Mañana, Medical Oncology Fellow, UCSF Helen Diller Family Comprehensive Cancer Center, Stephen Liu, Associate Professor of Medicine, Georgetown University, Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center, and Justin Gainor, Director, Center for Thoracic Cancers, Director of Targeted Immunotherapy, Associate Professor of Medicine at Harvard Medical School. In this series, the doctors discuss a variety of cases based on real-life scenarios. In this video Drs. Velazquez Mañana, Liu, and Gainor discuss the case…

For this year’s update to the Case-Based Panel Discussions program, we are pleased to work with Drs. Ana Velazquez Mañana, Medical Oncology Fellow, UCSF Helen Diller Family Comprehensive Cancer Center, Stephen Liu, Associate Professor of Medicine, Georgetown University, Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center, and Justin Gainor, Director, Center for Thoracic Cancers, Director of Targeted Immunotherapy, Associate Professor of Medicine at Harvard Medical School. In this series, the doctors discuss a variety of cases based on real-life scenarios. In this video Drs. Velazquez Mañana, Liu, and Gainor discuss the case…

For this year’s update to the Case-Based Panel Discussions program, we are pleased to work with Drs. Ana Velazquez Mañana, Medical Oncology Fellow, UCSF Helen Diller Family Comprehensive Cancer Center, Stephen Liu, Associate Professor of Medicine, Georgetown University, Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center, and Justin Gainor, Director, Center for Thoracic Cancers, Director of Targeted Immunotherapy, Associate Professor of Medicine at Harvard Medical School. In this series, the doctors discuss a variety of cases based on real-life scenarios. In this video Drs. Velazquez Mañana, Liu, and Gainor discuss the case…

For this year’s update to the Case-Based Panel Discussions program, we are pleased to work with Drs. Ana Velazquez Mañana, Medical Oncology Fellow, UCSF Helen Diller Family Comprehensive Cancer Center, Stephen Liu, Associate Professor of Medicine, Georgetown University, Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center, and Justin Gainor, Director, Center for Thoracic Cancers, Director of Targeted Immunotherapy, Associate Professor of Medicine at Harvard Medical School.  In this series, the doctors discuss a variety of cases based on real-life scenarios. In this video Drs. Velazquez-Manana, Liu, and Gainor discuss a 66-year-old patient…

We are excited to bring new and updated information to share through our Lung Cancer Video Library. For this video series, we are pleased to work with Dr. Christina Baik, Oncologist at Seattle Cancer Care Alliance, Associate Professor of Medicine at the University of Washington, and Associate Professor, Clinical Research Division of the Fred Hutchinson Cancer Care Research Center; Dr. Melina Marmarelis, Hematology and Oncology professional and Assistant Professor of Medicine at the Hospital of the University of Pennsylvania; Dr. Sandip Patel, Medical Oncologist and Associate Professor of Medicine at UC San Diego Health; Dr. Tejas Patil, Medical Oncologist and…

We are excited to bring new and updated information to share through our Lung Cancer Video Library. For this video series, we are pleased to work with Dr. Christina Baik, Oncologist at Seattle Cancer Care Alliance, Associate Professor of Medicine at the University of Washington, and Associate Professor, Clinical Research Division of the Fred Hutchinson Cancer Care Research Center; Dr. Melina Marmarelis, Hematology and Oncology professional and Assistant Professor of Medicine at the Hospital of the University of Pennsylvania; Dr. Sandip Patel, Medical Oncologist and Associate Professor of Medicine at UC San Diego Health; Dr. Tejas Patil, Medical Oncologist and…

We are excited to bring new and updated information to share through our Lung Cancer Video Library. For this video series, we are pleased to work with Dr. Christina Baik, Oncologist at Seattle Cancer Care Alliance, Associate Professor of Medicine at the University of Washington, and Associate Professor, Clinical Research Division of the Fred Hutchinson Cancer Care Research Center; Dr. Melina Marmarelis, Hematology and Oncology professional and Assistant Professor of Medicine at the Hospital of the University of Pennsylvania; Dr. Sandip Patel, Medical Oncologist and Associate Professor of Medicine at UC San Diego Health; Dr. Tejas Patil, Medical Oncologist and…

Sociodemographic: SABCS 2022 Megan Kruse Disparities in AYA Breast Cancer What does the sociodemographics present study of Adolescent and Young Adults (AYA) patients with invasive breast cancer tell us? This study was presented at the San Antonio Breast Cancer Symposium (SABCS) as a poster in 2022, and it’s a look at the effect of sociodemographic disparities on overall survival for adolescent and young adult patients with invasive breast cancer. So this is a unique population of patients within the breast cancer community. In the Adolescent and Young Adults (AYA) group, and we think about these patients age group are…

Sociodemographic: SABCS 2022 Megan Kruse Disparities in AYA Breast Cancer What does the sociodemographics present study of Adolescent and Young Adults (AYA) patients with invasive breast cancer tell us? This study was presented at the San Antonio Breast Cancer Symposium (SABCS) as a poster in 2022, and it’s a look at the effect of sociodemographic disparities on overall survival for adolescent and young adult patients with invasive breast cancer. So this is a unique population of patients within the breast cancer community. In the Adolescent and Young Adults (AYA) group, and we think about these patients age group are…

iFrame is not supported! Sociodemographic: SABCS 2022 Megan Kruse Disparities in AYA Breast Cancer What does the sociodemographics present study of Adolescent and Young Adults (AYA) patients with invasive breast cancer tell us? This study was presented at the San Antonio Breast Cancer Symposium (SABCS) as a poster in 2022, and it’s a look at the effect of sociodemographic disparities on overall survival for adolescent and young adult patients with invasive breast cancer. So this is a unique population of patients within the breast cancer community. In the Adolescent and Young Adults (AYA) group, and we think about…

DESTINY-Breast03: SABCS 2022 Sara Hurvitz Updated Survival Results What do the updated survival results deruxtecan versus trastuzumab emtansine reveal for this metastatic breast cancer clinical trial? The DESTINY-Breast03 clinical trial (Daiichi Sankyo and AstraZeneca’s Trastuzumab) was a phase 3 study comparing Trastuzumab Deruxtecan to Trastuzumab Emtansine in patients treated with HER2-positive metastatic breast cancer that had previously been treated with Trastuzumab and a taxane. The first analysis of the trial results were presented in September of 2021 at ESMO where a statistically significant improvement in progression-free survival was demonstrated with the hazard ratio of 0.28 in favor of T-DXd,…

iFrame is not supported! DESTINY-Breast03: SABCS 2022 Sara Hurvitz Updated Survival Results What do the updated survival results deruxtecan versus trastuzumab emtansine reveal for this metastatic breast cancer clinical trial? The DESTINY-Breast03 clinical trial (Daiichi Sankyo and AstraZeneca’s Trastuzumab) was a phase 3 study comparing Trastuzumab Deruxtecan to Trastuzumab Emtansine in patients treated with HER2-positive metastatic breast cancer that had previously been treated with Trastuzumab and a taxane. The first analysis of the trial results were presented in September of 2021 at ESMO where a statistically significant improvement in progression-free survival was demonstrated with the hazard ratio of…

DESTINY-Breast03: SABCS 2022 Sara Hurvitz Updated Survival Results What do the updated survival results deruxtecan versus trastuzumab emtansine reveal for this metastatic breast cancer clinical trial? The DESTINY-Breast03 clinical trial (Daiichi Sankyo and AstraZeneca’s Trastuzumab) was a phase 3 study comparing Trastuzumab Deruxtecan to Trastuzumab Emtansine in patients treated with HER2-positive metastatic breast cancer that had previously been treated with Trastuzumab and a taxane. The first analysis of the trial results were presented in September of 2021 at ESMO where a statistically significant improvement in progression-free survival was demonstrated with the hazard ratio of 0.28 in favor of T-DXd,…

GC012F: ASH 2022 Wendy Li First-Line Therapy Newly Diagnosed MM By Wendy Li, MD How can GC012F help patients with newly diagnosed multiple myeloma? This is a phase 1 open label single arm study of a BCMA/CD19 Dual-Targeting CAR T cells, FasTCAR-T therapy for first line therapy for transplant eligible high newly diagnosed multiple myeloma. What is the standard of care for patients with multiple myeloma? Yes, compare with the standard of the care. Yeah, I think the very important things to understand that’s a current standard of care. Yeah, for newly diagnosed multiple myeloma patients is a 6…

iFrame is not supported! GC012F: ASH 2022 Wendy Li First-Line Therapy Newly Diagnosed MM By Wendy Li, MD How can GC012F help patients with newly diagnosed multiple myeloma? This is a phase 1 open label single arm study of a BCMA/CD19 Dual-Targeting CAR T cells, FasTCAR-T therapy for first line therapy for transplant eligible high newly diagnosed multiple myeloma. What is the standard of care for patients with multiple myeloma? Yes, compare with the standard of the care. Yeah, I think the very important things to understand that’s a current standard of care. Yeah, for newly diagnosed multiple myeloma…

GC012F: ASH 2022 Wendy Li First-Line Therapy Newly Diagnosed MM By Wendy Li, MD How can GC012F help patients with newly diagnosed multiple myeloma? This is a phase 1 open label single arm study of a BCMA/CD19 Dual-Targeting CAR T cells, FasTCAR-T therapy for first line therapy for transplant eligible high newly diagnosed multiple myeloma. What is the standard of care for patients with multiple myeloma? Yes, compare with the standard of the care. Yeah, I think the very important things to understand that’s a current standard of care. Yeah, for newly diagnosed multiple myeloma patients is a 6…

IHC 0 HER2: SABCS 2022 Gerard Oakley Deep Learning-Based Assessment By Gerard Oakley, MD What is IHC 0 in HER2 breast cancer patients, and how can it help? So the current study is really an expansion on previous press releases that we’ve made about the development of an algorithm that we call HER2 complete which is designed to evaluate HER2-positive and negative breast cancer cases. And we’ve really aimed it for the IHC 0 category within HER2 testing. And so what we’ve done is we were able to access an additional 900 plus cases within IHC 0 from our collaboration…

iFrame is not supported! IHC 0 HER2: SABCS 2022 Gerard Oakley Deep Learning-Based Assessment By Gerard Oakley, MD What is IHC 0 in HER2 breast cancer patients, and how can it help? So the current study is really an expansion on previous press releases that we’ve made about the development of an algorithm that we call HER2 complete which is designed to evaluate HER2-positive and negative breast cancer cases. And we’ve really aimed it for the IHC 0 category within HER2 testing. And so what we’ve done is we were able to access an additional 900 plus cases within IHC…

IHC 0 HER2: SABCS 2022 Gerard Oakley Deep Learning-Based Assessment By Gerard Oakley, MD What is IHC 0 in HER2 breast cancer patients, and how can it help? So the current study is really an expansion on previous press releases that we’ve made about the development of an algorithm that we call HER2 complete which is designed to evaluate HER2-positive and negative breast cancer cases. And we’ve really aimed it for the IHC 0 category within HER2 testing. And so what we’ve done is we were able to access an additional 900 plus cases within IHC 0 from our collaboration…

CLL Treatments: ASH 2022 Brian Koffman Understanding Pts with CLL By Brian Koffman, MDCM (retired), DCFP, FCFP, DABFP, MSEd How will understanding patients with chronic lymphocytic leukemia (CLL) help with their treatments? First, I want to say I’m very thankful to have the opportunity to present this study on behalf of my co-investigators. We presented this as a poster presentation at ASH 2022 in New Orleans. The title is “Understanding Patient Preferences for Chronic Lymphocytic Leukemia Treatments.” In the way of background, I think all clinicians know how radically the treatment paradigm in CLL (chronic lymphocytic leukemia) has shifted over…

iFrame is not supported! CLL Treatments: ASH 2022 Brian Koffman Understanding Pts with CLL By Brian Koffman, MDCM (retired), DCFP, FCFP, DABFP, MSEd How will understanding patients with chronic lymphocytic leukemia (CLL) help with their treatments? First, I want to say I’m very thankful to have the opportunity to present this study on behalf of my co-investigators. We presented this as a poster presentation at ASH 2022 in New Orleans. The title is “Understanding Patient Preferences for Chronic Lymphocytic Leukemia Treatments.” In the way of background, I think all clinicians know how radically the treatment paradigm in CLL (chronic lymphocytic…

CLL Treatments: ASH 2022 Brian Koffman Understanding Pts with CLL By Brian Koffman, MDCM (retired), DCFP, FCFP, DABFP, MSEd How will understanding patients with chronic lymphocytic leukemia (CLL) help with their treatments? First, I want to say I’m very thankful to have the opportunity to present this study on behalf of my co-investigators. We presented this as a poster presentation at ASH 2022 in New Orleans. The title is “Understanding Patient Preferences for Chronic Lymphocytic Leukemia Treatments.” In the way of background, I think all clinicians know how radically the treatment paradigm in CLL (chronic lymphocytic leukemia) has shifted over…

Navitoclax: ASH 2022 Jalaja Potluri Disease Modification in Myelofibrosis By Jalaja Potluri, MD How can this study help modify myelofibrosis? Navitoclax is the investigational drug, which is not currently approved. It is being studied in a condition called Myelofibrosis. It’s a bone marrow disease where there’s changes in the blood counts and patients are symptomatic, with enlarged spleen. It is being studied in a phase 2 program, and the data that are being discussed are from this ongoing phase II study. It has multiple cohorts. The data that was just presented represents a population that has not yet received the…

iFrame is not supported! Navitoclax: ASH 2022 Jalaja Potluri Disease Modification in Myelofibrosis By Jalaja Potluri, MD How can this study help modify myelofibrosis? Navitoclax is the investigational drug, which is not currently approved. It is being studied in a condition called Myelofibrosis. It’s a bone marrow disease where there’s changes in the blood counts and patients are symptomatic, with enlarged spleen. It is being studied in a phase 2 program, and the data that are being discussed are from this ongoing phase II study. It has multiple cohorts. The data that was just presented represents a population that has…

Navitoclax: ASH 2022 Jalaja Potluri Disease Modification in Myelofibrosis By Jalaja Potluri, MD How can this study help modify myelofibrosis? Navitoclax is the investigational drug, which is not currently approved. It is being studied in a condition called Myelofibrosis. It’s a bone marrow disease where there’s changes in the blood counts and patients are symptomatic, with enlarged spleen. It is being studied in a phase 2 program, and the data that are being discussed are from this ongoing phase II study. It has multiple cohorts. The data that was just presented represents a population that has not yet received the…

TriTAC: ASH 2022 Al-Ola Abdallah Updated Interim Results HBN217 By Al-Ola Abdallah, MD What are the updated interim results from the HPN217 (Tri-specific T Cell Activating Construct [TriTAC®]) clinical trials in TRiTAC targeting BCMA for RRMM Patients in therapeutic T-cells? Today we’re gonna talk a little bit about HBN217 (Tri-specific T Cell Activating Construct [TriTAC®]), which is a TriSpecific T-cell activating construct and relapse refractory myeloma. And this type of treatment is designed for a phase 1 trial to evaluate the safety, tolerability, pharmacokinetics, and activity of this treatment. The mechanical action of this drug, it has three domains that…

iFrame is not supported! TriTAC: ASH 2022 Al-Ola Abdallah Updated Interim Results HBN217 By Al-Ola Abdallah, MD What are the updated interim results from the HPN217 (Tri-specific T Cell Activating Construct [TriTAC®]) clinical trials in TRiTAC targeting BCMA for RRMM Patients in therapeutic T-cells? Today we’re gonna talk a little bit about HBN217 (Tri-specific T Cell Activating Construct [TriTAC®]), which is a TriSpecific T-cell activating construct and relapse refractory myeloma. And this type of treatment is designed for a phase 1 trial to evaluate the safety, tolerability, pharmacokinetics, and activity of this treatment. The mechanical action of this drug, it…

TriTAC: ASH 2022 Al-Ola Abdallah Updated Interim Results HBN217 By Al-Ola Abdallah, MD What are the updated interim results from the HPN217 (Tri-specific T Cell Activating Construct [TriTAC®]) clinical trials in TRiTAC targeting BCMA for RRMM Patients in therapeutic T-cells? Today we’re gonna talk a little bit about HBN217 (Tri-specific T Cell Activating Construct [TriTAC®]), which is a TriSpecific T-cell activating construct and relapse refractory myeloma. And this type of treatment is designed for a phase 1 trial to evaluate the safety, tolerability, pharmacokinetics, and activity of this treatment. The mechanical action of this drug, it has three domains that…

Asciminib: ASH 2022 Prof. Hughes Studies For Pts With CML By Professor Timothy Hughes, MD, MBBS, FRACP, FRCPA How can Asciminib help patients with CML and were there any significant side effects? Asciminib is very much a new compound with a quite a unique mechanism of action, unlike all of the other Tyrosine kinase inhibitors (TKIs) which work by inhibiting BCR-ABL by competing with ATP, Asciminib actually binds to a distinct site in BCR-ABL, called the myristate site and switches off BCR-ABL activity by that mechanism. That provides a major advantage because you do not get the inhibition of other…

iFrame is not supported! Asciminib: ASH 2022 Prof. Hughes Studies For Pts With CML By Professor Timothy Hughes, MD, MBBS, FRACP, FRCPA How can Asciminib help patients with CML and were there any significant side effects? Asciminib is very much a new compound with a quite a unique mechanism of action, unlike all of the other Tyrosine kinase inhibitors (TKIs) which work by inhibiting BCR-ABL by competing with ATP, Asciminib actually binds to a distinct site in BCR-ABL, called the myristate site and switches off BCR-ABL activity by that mechanism. That provides a major advantage because you do not get…

Asciminib: ASH 2022 Prof. Hughes Studies For Pts With CML By Professor Timothy Hughes, MD, MBBS, FRACP, FRCPA How can Asciminib help patients with CML and were there any significant side effects? Asciminib is very much a new compound with a quite a unique mechanism of action, unlike all of the other Tyrosine kinase inhibitors (TKIs) which work by inhibiting BCR-ABL by competing with ATP, Asciminib actually binds to a distinct site in BCR-ABL, called the myristate site and switches off BCR-ABL activity by that mechanism. That provides a major advantage because you do not get the inhibition of other…

Liso-cel: ASH 2022 Data From the Outreach Study By Yuliya Linhares, MD How can Liso-Cell (Lisocabtagene Maraleucel) help patients with RR large B-cell lymphoma? Today I’m going to be talking about the outreach study. So outreach study is the phase 2 prospective study evaluating the safety and efficacy of treatment with chimeric antigen receptor T-cell therapy Lisocabtagene Maraleucel (Liso-cel). Liso-cel (Liscobtagene Maraleucel) in patients with third line or later relapse or refractory large B-cell lymphoma across outpatient and inpatient setting at community or non university sites in the United States. So we know that we can give CAR T-cell…

iFrame is not supported! Liso-cel: ASH 2022 Data From the Outreach Study By Yuliya Linhares, MD How can Liso-Cell (Lisocabtagene Maraleucel) help patients with RR large B-cell lymphoma? Today I’m going to be talking about the outreach study. So outreach study is the phase 2 prospective study evaluating the safety and efficacy of treatment with chimeric antigen receptor T-cell therapy Lisocabtagene Maraleucel (Liso-cel). Liso-cel (Liscobtagene Maraleucel) in patients with third line or later relapse or refractory large B-cell lymphoma across outpatient and inpatient setting at community or non university sites in the United States. So we know that we…

Liso-cel: ASH 2022 Data From the Outreach Study By Yuliya Linhares, MD How can Liso-Cell (Lisocabtagene Maraleucel) help patients with RR large B-cell lymphoma? Today I’m going to be talking about the outreach study. So outreach study is the phase 2 prospective study evaluating the safety and efficacy of treatment with chimeric antigen receptor T-cell therapy Lisocabtagene Maraleucel (Liso-cel). Liso-cel (Liscobtagene Maraleucel) in patients with third line or later relapse or refractory large B-cell lymphoma across outpatient and inpatient setting at community or non university sites in the United States. So we know that we can give CAR T-cell…

RxPONDER: SABCS 2022 Yara Abdou Racial Disparities SWOG S1007 The focus was on patient-reported anxiety and fatigue in women, what were the findings? Our study was focused on determining whether there were racial or ethnic disparities in patient outcomes in the RxPONDER trial. As a reminder, the RxPONDER trial is what established the clinical utility of the 21-gene recurrence score in participants with hormone positive HER2 negative breast cancer and 1–3 positive lymph nodes. Our study objectives were to evaluate the entire cohort for clinical and pathologic characteristics by race, analyze the clinical outcomes by race, and…

iFrame is not supported! RxPONDER: SABCS 2022 Yara Abdou Racial Disparities SWOG S1007 The focus was on patient-reported anxiety and fatigue in women, what were the findings? Our study was focused on determining whether there were racial or ethnic disparities in patient outcomes in the RxPONDER trial. As a reminder, the RxPONDER trial is what established the clinical utility of the 21-gene recurrence score in participants with hormone positive HER2 negative breast cancer and 1–3 positive lymph nodes. Our study objectives were to evaluate the entire cohort for clinical and pathologic characteristics by race, analyze the clinical…

RxPONDER: SABCS 2022 Yara Abdou Racial Disparities SWOG S1007 The focus was on patient-reported anxiety and fatigue in women, what were the findings? Our study was focused on determining whether there were racial or ethnic disparities in patient outcomes in the RxPONDER trial. As a reminder, the RxPONDER trial is what established the clinical utility of the 21-gene recurrence score in participants with hormone positive HER2 negative breast cancer and 1–3 positive lymph nodes. Our study objectives were to evaluate the entire cohort for clinical and pathologic characteristics by race, analyze the clinical outcomes by race, and…

Endocrine Therapy: SABCS 2022 Halle Moore POSITIVE Trial Breast Cancer How does endocrine therapy (aromatase inhibitor) effect women with endocrine responsIVE breast cancer? The POSITIVE study which was presented at this year’s San Antonio Breast Cancer Symposium (SABCS) was a prospective clinical trial designed to evaluate the safety of and pregnancy outcomes with interrupting endocrine therapy for early stage hormone receptor positive breast cancer in order to attempt pregnancy. Young women with early stage hormone receptor positive breast cancer were eligible for the trial if they desired pregnancy and had completed 18 to 36 months of adjuvant endocrine therapy.…

iFrame is not supported! Endocrine Therapy: SABCS 2022 Halle Moore POSITIVE Trial Breast Cancer How does endocrine therapy (aromatase inhibitor) effect women with endocrine responsIVE breast cancer? The POSITIVE study which was presented at this year’s San Antonio Breast Cancer Symposium (SABCS) was a prospective clinical trial designed to evaluate the safety of and pregnancy outcomes with interrupting endocrine therapy for early stage hormone receptor positive breast cancer in order to attempt pregnancy. Young women with early stage hormone receptor positive breast cancer were eligible for the trial if they desired pregnancy and had completed 18 to 36…

Endocrine Therapy: SABCS 2022 Halle Moore POSITIVE Trial Breast Cancer How does endocrine therapy (aromatase inhibitor) effect women with endocrine responsIVE breast cancer? The POSITIVE study which was presented at this year’s San Antonio Breast Cancer Symposium (SABCS) was a prospective clinical trial designed to evaluate the safety of and pregnancy outcomes with interrupting endocrine therapy for early stage hormone receptor positive breast cancer in order to attempt pregnancy. Young women with early stage hormone receptor positive breast cancer were eligible for the trial if they desired pregnancy and had completed 18 to 36 months of adjuvant endocrine therapy.…

iFrame is not supported! IPSS: ASH 2022 Roger Lyons Treatment Pattern and Overall Survival MDS By Roger M. Lyons, MD, FACP What is the IPSS and the IPSS-R scoring systems and how will this help patients with MDS? This is a study that took place over 10 years looking at the US Oncology iKnowMed medical record system to define the course of patients with a myelodysplasia. There were 1400 physicians involved in the trial. So it’s a huge database. Of course, this was not a prospective study, so some of the data is not absolutely in a form that…

iFrame is not supported! IPSS: ASH 2022 Roger Lyons Treatment Pattern and Overall Survival MDS By Roger M. Lyons, MD, FACP What is the IPSS and the IPSS-R scoring systems and how will this help patients with MDS? This is a study that took place over 10 years looking at the US Oncology iKnowMed medical record system to define the course of patients with a myelodysplasia. There were 1400 physicians involved in the trial. So it’s a huge database. Of course, this was not a prospective study, so some of the data is not absolutely in a form that…

IPSS: ASH 2022 Roger Lyons Treatment Pattern and Overall Survival MDS By Roger M. Lyons, MD, FACP What is the IPSS and the IPSS-R scoring systems and how will this help patients with MDS? This is a study that took place over 10 years looking at the US Oncology iKnowMed medical record system to define the course of patients with a myelodysplasia. There were 1400 physicians involved in the trial. So it’s a huge database. Of course, this was not a prospective study, so some of the data is not absolutely in a form that can you be used…

Caplacizumab: TMA Camila Masias ASH 2022 HRES Discussion By Camila Masias, MD How will Caplacizumab help patients with TMAs? I will be discussing the diagnosis and treatment of pregnant women with a prior diagnosis of TMAs, or thrombotic microangiopathy. This is very important because while thrombotic microangiopathy, specifically TTP and complement mediated HRES, are rare disease in these patients. Eventually, want to become pregnant, and there’s a number of uncertainties in this field. Should we monitor them? How do we monitor them? How frequently, what labs do we use for that? And the reality is that compliment plays an…

iFrame is not supported! Caplacizumab: TMA Camila Masias ASH 2022 HRES Discussion By Camila Masias, MD How will Caplacizumab help patients with TMAs? I will be discussing the diagnosis and treatment of pregnant women with a prior diagnosis of TMAs, or thrombotic microangiopathy. This is very important because while thrombotic microangiopathy, specifically TTP and complement mediated HRES, are rare disease in these patients. Eventually, want to become pregnant, and there’s a number of uncertainties in this field. Should we monitor them? How do we monitor them? How frequently, what labs do we use for that? And the reality is…

Caplacizumab: TMA Camila Masias ASH 2022 HRES Discussion By Camila Masias, MD How will Caplacizumab help patients with TMAs? I will be discussing the diagnosis and treatment of pregnant women with a prior diagnosis of TMAs, or thrombotic microangiopathy. This is very important because while thrombotic microangiopathy, specifically TTP and complement mediated HRES, are rare disease in these patients. Eventually, want to become pregnant, and there’s a number of uncertainties in this field. Should we monitor them? How do we monitor them? How frequently, what labs do we use for that? And the reality is that compliment plays an…

FGFR2: Breast Cancer Suneel Kamath SABCS 2022 ReFocus Trial How can FGFR2 inhibitors like RLY-4008 help with patients suffering with cholangiocarcinoma and what makes it a clinical significance? The ReFocus study is a trial, it’s a phase 1/2B study including all solid tumors, mainly focused on cholangiocarcinoma, and some other separate subsets including breast cancer, some of the GYN malignancies as well. Looking at a novel FGFR2 inhibitor RLY-4008. So there are several existing FGFR2 (tyrosine kinase) inhibitors in cholangiocarcinoma and bladder cancer. And all of them look to be quite effective and really great treatment options, but many…

iFrame is not supported! FGFR2: Breast Cancer Suneel Kamath SABCS 2022 ReFocus Trial How can FGFR2 inhibitors like RLY-4008 help with patients suffering with cholangiocarcinoma and what makes it a clinical significance? The ReFocus study is a trial, it’s a phase 1/2B study including all solid tumors, mainly focused on cholangiocarcinoma, and some other separate subsets including breast cancer, some of the GYN malignancies as well. Looking at a novel FGFR2 inhibitor RLY-4008. So there are several existing FGFR2 (tyrosine kinase) inhibitors in cholangiocarcinoma and bladder cancer. And all of them look to be quite effective and really great…

FGFR2: Breast Cancer Suneel Kamath SABCS 2022 ReFocus Trial How can FGFR2 inhibitors like RLY-4008 help with patients suffering with cholangiocarcinoma and what makes it a clinical significance? The ReFocus study is a trial, it’s a phase 1/2B study including all solid tumors, mainly focused on cholangiocarcinoma, and some other separate subsets including breast cancer, some of the GYN malignancies as well. Looking at a novel FGFR2 inhibitor RLY-4008. So there are several existing FGFR2 (tyrosine kinase) inhibitors in cholangiocarcinoma and bladder cancer. And all of them look to be quite effective and really great treatment options, but many…

Bisphosphonates: Breast Cancer Julia Foldi SABCS 2022 Cohort Study How can BMAs (zoledronic acid) help oncology patients with early-stage breast cancer in the United States and not in other countries? I’m talking about our study looking at patterns of adjuvant bone modifying use in patients with early stage breast cancers. Bone modifying agents, particularly bisphosphonates, not only help preserve bone density (or bone material loss) in postmenopausal women receiving endocrine therapy for treatment of breast cancer, but we also know that they reduce the risk of breast cancer recurrence as well as reduce the risk of breast cancer specific…

iFrame is not supported! Bisphosphonates: Breast Cancer Julia Foldi SABCS 2022 Cohort Study How can BMAs (zoledronic acid) help oncology patients with early-stage breast cancer in the United States and not in other countries? I’m talking about our study looking at patterns of adjuvant bone modifying use in patients with early stage breast cancers. Bone modifying agents, particularly bisphosphonates, not only help preserve bone density (or bone material loss) in postmenopausal women receiving endocrine therapy for treatment of breast cancer, but we also know that they reduce the risk of breast cancer recurrence as well as reduce the risk…